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Summary.
The metabolic processes involved in the production of 
oxalate from its major precursors were reviewed, and the 
analytical techniques used for the analysis of oxalate in 
biological material examined.
An automated enzymic procedure for urinary oxalate 
utilising oxalate decarboxylase and formate dehydrogenase 
was developed and evaluated using the reference method. 
The chosen procedure was subsequently employed for the 
determination of oxalate in urine obtained from a group of 
volunteers free of a history of stone formation and other 
disorders. A wide variation of oxalate excretion both 
within and between individuals was noted.
The reference procedure was used for urine oxalate 
analyses of 24 hour collections from 3 groups of stone 
formers ascribed one of two therapies; allopurinol or 
bendrofluazide. Biochemical tests of serum (calcium, 
magnesium, zinc and urate concentrations) and urine 
(calcium, magnesium creatinine and urate excretion) were 
also undertaken.
Efficacy of the above therapies in reducing stone 
recurrence rates was implied in this study although the 
reasons for these effects were not clear.
The use of allopurinol and bendrofluazide as 
effective agents in reducing urinary oxalate was not 
confirmed by this work.
(18)
CHAPTER 1. GENERAL INTRODUCTION.
1. UPPER URINARY TRACT STONE DISEASE.
1.1 .Significance
Upper urinary tract stone disease which occurs 
within the kidney and ureter has apparently been known
since the times of the Ancient Egyptians and Hippocrates.
Currently, in the western countries, some 2 - 3 % of
people will develope a urinary tract stone at some time in 
their lives (Nordin and Hodgkinson 1972). It has been
suggested that stones occur equally in both the sexes 
(Lonsdale 1968) although most workers have found that 
symptomatic stones are between 2 and 5 times as common in
men as in women (Hodgkinson 1977, Robertson et al 1980a).
The appearance of concretions within the urinary
tract may not in themselves be life threatening . However
loss of kidney function may occur due to damage to the 
kidney caused by chronic obstruction, infection or 
surgical intervention; moreover although the disease 
itself may be managed successfully, the treatment 
necessary, such as surgical removal of a stone, may carry 
serious risks.
The pain associated with kidney stones, 'renal 
colic', is extreme; 'in all of clinical practice there is 
no worse pain encountered' (Coe 1980).
The peak age for the occurrence of stones has been
(19)
shown to be 35 years in men. In women a double peak has 
been observed at 30 and 55 years; there was a low 
incidence of stones in the elderly and in children, in 
developed societies (Robertson et al 1980a).
The disease is of a recurrent nature: some 15 % of 
stone formers were seen to have had a second stone 
incident within a year of the first episode, 42 - 48 % of 
the same group within 4 years and within 9 years 61 - 67 % 
were found to have had a recurrence (Coe 1980).
Stone disease is therefore likely to afflict a 
small but economically important group of society. An 
active therapeutic scheme to reduce the -
recurrence of this condition must be considered as 
worthwhile.
1.2. Types of stone.
In a review of clinical stone disease by Coe 
(1980) 4 types of stone were recognised, containing
predominantly calcium, struvite (magnesium ammonium 
phosphate,MgNH4P04.6H20) , uric acid or cystine. The 
percents occurrence of each type from a total of 1870 
stones primarily from the United States and Europe are 
shown in table 1.1. Although these are not absolute values 
they are in general agreement with the values suggested by 
Nordin and Hodgkinson (1972) from a study of 700 calculi 
and Hodgkinson (1977) from a study of 157 calculi.
The calcium stones may be further subdivided into
(20)
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those that contain predominantly calcium oxalate, a 
mixture of calcium oxalate and calcium phosphate, and 
predominantly calcium phosphate stones. The percents 
occurrence of these stone types, displayed in table 1.2. 
(Coe 1980) show that, next to calcium, oxalate is the most 
frequently occurring component of renal stone and may be 
expected to be seen in over 60 % of all calculi.
Xanthine stones and 2,8, dihydroxyadenine stones 
have also been recognised but the occurrence rate of these 
types was less than 1 % (Silcock 1980).
1.3. Major causes of renal stone.
The underlying cause of all urinary tract stone
formation is supersaturation of the urine with a poorly
soluble material modified, in the case of calcium stones, 
by the presence or absence of crystallisation inhibitors 
and sources of seed crystals and in the case of struvite 
stones by the presence or absence of a urinary tract 
infection (Coe 1980).
The rare 2,8,dihydroxyadenine stones occur due to a 
congenital enzymatic abnormality in which there is a
complete lack of adenine phosphoribosyltransferase (E.C.
2.4.2.7.). In this disorder adenine is converted to 2,8, 
dihydroxyadenine by xanthine oxidase (E.C. 1.2.3.2.). The 
congenital enzymatic deficiency of xanthine oxidase leads 
to xanthinuria and subsequent xanthine stone formation 
(Silcock 1980). A congenital disorder of cystine,
(21)
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arginine, lysine and ornithine transport affecting the 
epithelial cells of the renal tubules and the
gastrointestinal tract leads to 'cystinuria' and the 
formation of cystine containing stones (Halperen and Thier 
1980).
Uric acid stones occur when there is over­
saturation of the urine with urate due to disorders of
uric acid metabolism, reduced urine volume or a low
urinary pH.
Struvite or 'infection' stones are considered to 
be the result of urinary infection with bacteria that 
possess urease (E.C. 3.5.1.5.). This enzymic splitting of 
urea leads to a combination of high urinary pH and 
ammonium concentration. Such stones also contain -alcium 
.phosphate (Silcock 1980, Coe 1980).
Calcium phosphate stones tend to occur in urine 
which is abnormally alkaline due to an acidification 
defect or a urinary tract infection (Silcock 1980). 
Calcium oxalate stones, in the pure or mixed forms, may be 
due to disturbances in calcium and / or oxalate metabolism 
leading to hypercalciuria and hyperoxaluria with 
subsequent stone formation. As mixed stones may contain 
significant amounts of urate, hyperuricosuria may also 
induce calcium stones (Silcock 1980, Coe 1980).
1.4. Idiopathic stone disease.
When there is no recognisable clinical pathology
(22)
to account for the formation of renal stones, as is the 
case for the majority of calcium stone formers, such 
subjects have been described as 'idiopathic1 stone formers 
(Silcock 1980). However, a number of 'risk factors' 
relating to urinary composition, which predispose subjects 
to form stones, have been recognised.
Robertson et al (1980a), describing calcium stone 
formation as a multifactorial disorder, recognised six 
main urinary risk factors: low volume, high pH, increased 
excretion of calcium, increased excretion of oxalate, 
increased excretion of uric acid and the decreased 
excretion of calcium oxalate crystallisation inhibitors, 
particularly glycosaminoglycans (acid
mucopolysaccharides).
These factors influenced the relative saturation 
of urine with stone forming constituents, and the major 
risk factor was considered to be the saturation of urine 
with oxalate (Robertson et al 1980a, Robertson et al 
1980b, Robertson et al 1981), as a small change in the 
urinary oxalate would be responsible for a relatively 
large change in the overall 'risk' of forming stones.
2. SOURCES OF OXALATE IN MAN.
Oxalic acid is the simplest of the dicarboxylic 
acids (figure 1.1.). In nature, it rarely occurs as the 
free acid, but is more often seen as some form of oxalate 
salt. In this work, the term "oxalate" will be used
(23)
CO OH
CQOI-I
FIGURE' X. 1'/ STRUCTURAL FORMULA OF ANHYDROUS 'O^ LTC"XC'IEj
generally to describe the acid and its salts, unless a 
more specific name is required to differerentiate a
particular form of oxalate.
The excretion of oxalate from the animal body has
been recognised to be important in a number of
pathological conditions, but in general, studies have been 
hindered by the lack of a suitable routine oxalate assay.
There are two sources of oxalate in man, direct 
dietary intake, and endogenous synthesis. Each will be 
described separately.
2.1. Direct dietary intake.
2.1.1. Oxalate in the diet.
Several estimates have been made of the oxalate 
content of the diet (Kohmann 1939, Andrews and Viser 1951, 
Zarembski and Hodgkinson 1962, Kasidas and Rose 1980). The 
values are in general aggreement with each other, although 
the use of a more recent method of analysis employing the 
enzyme oxalate decarboxylase (E.C.4.1.1.2.) (Kasidas and 
Rose 1980) produced results which were generally higher 
than those in the earlier reports. Particular foodstuffs, 
such as spinach, parsley, beetroot, rhubarb and chocolate 
may be considered rich in oxalate, whilst meat and dairy 
products contain only low concentrations. Tea, with
(24)
moderately elevated levels of oxalate, has been considered 
to be a major source of dietary oxalate for the English 
(Hodgkinson 1977) and the specific oxalate concentration 
for a particular tea has been shown to increase with the
time of infusion (Kasidas and Rose 1980).
Oxalate occurs in plants in two main forms; the
water soluble fraction, predominantly the sodium and
potassium salts with some as the ammonium salt, and the
water insoluble fraction, mainly the calcium salt with
small amounts as the magnesium salt. The free acid, as 
such, rarely occurs in plants, and then only in trace 
amounts. The oxalate content of a particular plant has
been shown to depend on the variety, age, climate, soil 
conditions and the parts analysed (Oke 1969).
The average oxalate content of the English diet 
has been estimated to be 1080 umol/d (range^go - 1670 umo 1/d) 
predominantly from tea with bread and potatoes as other 
major sources (Zarembski and Hodgkinson 1962).
2.1.2. Intestinal absorption.
In vitro studies of rabbit intestinal mucosa and 
everted gut sacs from the rat, have shown oxalate uptake 
to be a passive, non energy dependant, non saturatable 
process (Binder 1974).
For absorption to occur, the oxalate must be in an 
available ie. soluble, form, but in the normal subject 
this is not generally the case. Absorption of oxalate from
(25)
the intestine has been shown to be poor, some 5 % or less 
of dietary oxalate being excreted in the urine of normal 
subjects following a normal diet (Hagler and Hermann 
1973b). Under normal conditions, a high proportion of the 
dietary oxalate is precipitated in the lumen by dietary 
calcium, but if calcium intake is restricted then the 
oxalate excretion in the urine has been shown to rise in 
man (Zarembski and Hodgkinson 1962, Hodgkinson 1977), and 
in rats (Ribaya and Gershoff 1982). After an oral dose of 
soluble sodium oxalate, subjects following a normal diet 
demonstrated a rise in urinary oxalate of 2.3 - 4.5 % of 
the administered dose (Archer et al 1957, Zarembski and 
Hodgkinson 1962) whereas subjects who had been fasted 
overnight showed an increase of 13.6 _+ 5.9 % of the
administered dose (Tiselius et al 1981). The marked 
difference between the two studies was explained by the 
inhibitory effect of dietary calcium on oxalate uptake, 
which occurred ' due to the precipitation of insoluble 
calcium oxalate at pH above 3.0 (Oke 1969) under which 
condititions both the calcium and oxalate were unavailable 
for absorption. Further evidence of this effect was shown 
by Chadwick, Modha and Dowling (1973) who demonstrated 
that non fasted human subjects absorbed 6.0 _+ 0.9 % of an 
oral supplement of [14-C] labelled oxalate whereas fasted 
subjects absorbed 28.0 3.2 %. This may explain the
observation of a negative correlation (r = -0.6) between 
the frequency of urolithiasis and the hardness of the 
water shown in a number of regions in the United States
(26)
(Dobson and Finlayson, 1973).
In man, the ingestion of oxalate rich foods impaired 
the intestinal absorption of calcium from other dietary 
sources, presumably due to the information of insoluble 
calcium oxalate (Pingle and Ramasastri, 1978). In the rats 
on high dietary oxalate intake mortality was significantly 
increased. The observed softening of the bones and reduced 
calcification of teeth suggested a marked bone resorption. 
No bone changes were noted in the control group (Kohman 
1939).
In patients with ileocecal resection, absorption of 
an oxalate supplement has been show to be raised to 
18.3 + 7.0% and to 36.8 + 14.0% in those with jejunoileal 
bypass. In the control group the absorption was 13.6 + 5.9% 
of the administered dose (Tiselius et al 1981). The reason 
for such an increase may be the presence of additional sites 
of oxalate absorption along the intestinal tract. Long 
chain
(27)
fatty acids have been shown to increase the absorption of 
oxalate possibly by chelating calcium (Binder 1974). The 
calcium was therefore no longer free to complex with 
oxalate and the free, soluble oxalate was therefore 
available for passive absorption.
2.2. Endogenous synthesis.
A number of oxalate precursors have been 
recognised in man and in animals. Compounds such as 
glycine, gelatin, glyoxylic acid, glycollic acid , ethylene 
glycol, ascorbic acid, certain amino acids (tryptophan, 
hydroxyproline, phenylalanine, tyrosine, threonine, 
aspartic acid, and asparagine), creatinine, purines, 
glucose and other carbohydrates have all been suggested as 
precursors of oxalate (Hagler and Herman 1973a, Hodgkinson 
1977).
However, only two routes of production appear to 
be of significant importance in the . human; these
are the oxidative metabolism of ascorbic acid and the 
direct oxidation of glyoxylic acid. -
2.2.1. From ascorbate.
Oxalate has been shown to be a metabolite of 
L-ascorbic acid (vitamin C) in the rat (Curtin and King 
1955, Gamberdella and Richardson 1977, Hodgkinson 1978), 
guineapig (Banay and Dimant 1962), monkey (Tillotson and
(28)
McGown 1981), and man (Heilman and Burns 1958, Baker et al 
1962, Abt, von Schuching and Enns 1963, Atkins et al 1964, 
Baker et al 1966a). Some 17 to 40 % of labelled L-ascorbic 
acid was excreted as labelled urinary oxalate, accounting 
for some 40 to 50 % of the total urinary oxalate excretion 
in normal adults (Baker et al 1962, Atkins et al 1964, 
Baker, Saari and Tolbert 1966b).
Radiotracer studies using [14-C] and [13-C] 
labelled ascorbate have shown that the oxalate was derived 
from carbon atoms one and two of the ascorbate molecule 
(Banay and Dimant 1962), presumably by the cleavage of the 
carbon number two to the carbon number three bond, but the 
pathway by which this was reached is not fully understood, 
and may vary between animal species (Heilman and Burns 
1958) .
The two isomers of ascorbic acid have been shown 
to behave differently in the animal body. The retention of 
intraperitoneally administered D-ascorbic acid has been 
shown to be considerably less than that of the L-isomer in 
the guineapig and the rat (Dayton and Burns 1958). This 
finding may explain the lack of vitamin C "activity" of 
the D-isomer. The vitamin C "activity" of certain other 
analogues of L-ascorbic acid in the guineapig has been 
shown to be dependent upon their retention (Zilva 1935) .
The oxidation of labelled carbon atoms in 
L-ascorbic acid to respiratory carbon dioxide has been 
demonstrated in the guineapig and the rat (Dayton and 
Burns 1958, Heilman and Burns 1958, Dayton, Eisenberg and
(29)
Burns 1959, Gambardella and Richardson 1977) . A similar 
finding has been shown in man (Abt et al 1963), but on 
further investigation was not reproduced (Heilman and 
Burns 1958, Baker et al 1966a). Baker et al (1966a) 
attributed these contradictory findings of carbon dioxide 
production from ascorbate by Abt et al (1963) to
impurities in the ascorbic acid used by the latter. Baker 
et al (1966a) further proposed that the mechanism for the 
breakdown of ascorbic acid in man was as shown in figure
1.2., where the ascorbate was enzymatically reduced, in 
the presence of oxygen, to dehydroascorbic acid which 
remained bound to the enzyme; the carbon number two to
carbon number three cleavage occurred whilst the lactone 
ring was still intact. It has been shown in rats that 
neither glycollate nor glyoxylate was involved in the 
breakdown of ascorbic acid (Gambardella and Richardson 
1977), and in man that diketogulonic acid, an intermediate 
in the non-enzymic oxidative decomposition of ascorbic 
acid in aqueous solution, was not a urinary metabolite
(Baker et al 1971).
2.2 .2 . From glyoxylate.
Glyoxylate may be metabolised via a number of 
pathways, to a number of intermediates / products. 
However, it is the metabolism of glyoxylate to oxalate
that will be reviwed here.
Glyoxylate has been shown to be a precursor of
(30)
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oxalate in the rat (Weinhouse and Freidman 1951, Nakada 
and Weinhouse 1953, Hodgkinson 1978, Gambardella and 
Richardson 1978) and in man (Dean, Watts and Westwick 
1968, King and Wainer 1968) using radiolabelled 
glyoxylate. The contribution of glyoxylate metabolism to 
the total oxalate excretion will vary depending on the 
presence of a number of glyoxylate precursors and 
glyoxylate forming reactions, but has been estimated to 
account for some 60 % of the urinary oxalate in a normal 
subject receiving a normal diet (Hodgkinson and Zarembski 
1968) .
Three enzymes, lactate dehydrogenase
(E.C.1.1.1.27.), glycollate oxidase (E.C. 1.1. 3.1.)" and
xanthine oxidase (E.C.1.2.3.2.), isolated from human and 
animal tissues, have been shown to be able to catalyse the 
oxidation of glyoxylate to oxalate.
Lactate dehydrogenase appears to be,
quantitatively, the most important. A preparation from pig 
heart has been shown to catalyse the reduction of 
glyoxylate to glycollate, requiring NADH at a pH optimum 
of 6.9, and the oxidation of glyoxylate to oxalate,
requiring NAD at a pH optimum of 9.3. Oxalate itself was a 
non-competitive inhibitor of the glyoxylate reduction, and 
a competitive inhibitor of the oxidation (Warren 1970). 
The activity of lactate dehydrogenase from the soluble 
fraction of liver tissues, has been shown to be 100,000
times greater in affecting the oxidation of glyoxylate
than that of either xanthine oxidase or glycollate oxidase
(31)
from similar preparations of human liver and heart tissue 
(Gibbs 1971) .
Glycollate oxidase, a flavoprotein, catalyses the 
conversion of glycollate to glyoxylate by molecular oxygen 
(Kun, Dechary and Pitot 1954), as well as the oxidation of 
glyoxylate to oxalate. Again, there was product inhibition 
of this oxidation by the oxalate (Richardson and Tolbert 
1961). Although in the human system, lactate dehydrogenase 
was considered to be the most important enzyme, it has 
been shown, in isolated perfused rat liver, using specific 
inhibitors, that glycollate oxidase was of greater
significance in this system, as well as being involved in
the synthesis of oxalate from ethylene glycol, glycine, 
serine, and ethanolamine (Liao and Richardson 1973) .
Xanthine oxidase, another flavoprotein, also 
catalyses the conversion of glyoxylate to oxalate. In 
vitro studies have shown inhibition of oxalate production 
by the xanthine oxidase inhibitor allopurinol, although 
this inhibition was more extensive in enzyme preparations 
from milk than in those from the supernatant fraction of
human liver (Gibbs and Watts 1966). However, the in vivo
administration of allopurinol over a two week period of 
time did not reduce the oxalate excretion in four adult 
male stone formers (King and Wainer 1968), nor in two 
gouty subjects, and oxalate excretion was still evident in 
patients where the xanthine oxidase enzyme was 
congenitally absent. It therefore appears that in the
human subject xanthine oxidase plays a minor role
(32)
(Gibbs and Watts 1966) .
More recently a fourth enzyme, L-2-hydroxy acid 
oxidase (E.C. 1.1. 3.15." from rat kidney, has been shown
to utilise a number of thiol glyoxylate adducts as 
substrates to produce oxalyl thioesters. These thioesters 
may eventually be broken down to produce oxalate, and this 
may be another pathway of oxalate formation from 
glyoxylate (Brush and Hamilton 1981).
The formation of oxalate from glyoxylate is not 
the major pathway of glyoxylate metabolism in normal 
subjects (King and Wainer 1968) , and the alternate 
pathways are important, as they point to possible 
mechanisms for the jLn vivo accumulation of glyoxylate 
(Williams and Smith 1978).
The relevant metabolic pathways involved in the 
synthesis of oxalate and the metabolism of glyoxylate in 
man are shown in figure 1.3.
2.3.Increased endogenous synthesis.
2.3.1.Primary hyperoxaluria.
Primary hyperoxaluria is a general term for two 
genetic disorders of glyoxylate metabolism which are 
characterised by recurrent calcium nephrolithiasis, 
chronic renal failure and early death from uraemia 
(Williams and Smith 1978). The two discrete disorders have 
been classified as primary hyperoxaluria type I and type
(33)
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Primary hyperoxaluria type I (glycolic aciduria) 
has been shown to be due to an inherited defect of 
cytoplasmic 2-oxoglutarateicarboligase activity, which 
converts glyoxylate to keto- -hydroxy adipate (figure 
1.3). This leads to an accumulation of glyoxylate and 
secondarily to an increased biosynthesis of oxalate and 
glycollate (Hodgkinson 1977, Williams and Smith 1978).
Primary hyperoxaluria type II (L-glyceric 
aciduria) is also an inherited disorder. The metabolic 
lesion has been less well defined, but it was suggested 
that a deficiency of D-glycerate dehydrogenase, which 
catalyses the interconversion of hydroxypyruvate and 
D-glycerate, as found in the leucocytes of patients with 
L-glyceric aciduria, was responsible for an increased 
hydroxypyruvate level and its subsequent increased 
reduction to L-glyceric acid (Williams and Smith 1978) . 
The increase in the oxalate excretion was less clear, but 
Liao and Richardson (1972) have shown that hydroxypyruvate 
may be converted to oxalate therefore an increased level 
of hydroxypyruvate was responsible for an increased level 
of oxalate (Liao and Richardson 1978) . Williams and Smith
(1978) suggested that this increased oxalate synthesis was 
a result of the non specific reactivity of certain enzymes 
such as lactate dehydrogenase with hydroxypyruvate and 
glyoxylate; the reduction of hydroxypyruvate to 
L-glycerate by lactate dehydrogenase with the production 
of NAD favoured the oxidation of glyoxylate to oxalate
(34)
with the production of NADH by the same enzyme. However, 
more recently, hydroxypyruvate has been shown to inhibit 
the production of oxalate from glyoxylate by lactate 
dehydrogenase _in vitro (Raghavan and Richardson 1983b).
The nonenzymic auto-oxidation of hydroxypyruvate 
has been sugested as another mechanism of oxalate 
formation (Raghavan and Richardson 1983a), as has the 
observation that hydroxypyruvate may bring about the 
decarboxylation of glyoxylate to oxalate by two 
non-enzymic mechanisms (Raghavan and Richardson 1983b).
2.3.2.Acquired hyperoxaluria.
Acquired hyperoxaluria may be regarded as
'secondary1 to a 'primary* abnormal nutritional state 
(Williams and Smith 1978). As stated earlier, oxalate 
excretion may be increased by the ingestion or
hyperabsorption of oxalate. Similarly,' endogenous 
synthesis may be increased by the ingestion or
hyperabsorption of oxalate precursors.
In section 2.2.1., ascorbate has been shown to
give rise to oxalate. However, ethylene glycol, an 
anti-freeze agent (Parry and Wallach 1974, Gambardella and 
Richardson 1978) and methoxyflurane, a general anaesthetic 
(Frascino, Vanamee and Rosen 1971, McIntyre, Russell and
Chambers 1973,) have also been shown to be metabolised to 
oxalate.
Vitamin B6 (pyridoxine) has been shown to be
(35)
required for the transamination of glyoxylate to glycine 
(Hodgkinson 1977) and pyridoxine deficiency has been shown 
to lead to hyperoxaluria in animals (Gershoff et al 1959) 
and man (Faber et al 1963).
3.ANALYTICAL METHODS.
Many procedures have been described for the 
analysis of oxalate, involving a variety of analytical 
techniques. Most of these procedures required preliminary 
separation of the oxalate from interfering substances;
labelled oxalic acid has been frequently used as a
recovery marker. This has increased the complexity of many 
of the procedures.
3.1. Atomic absorption.
Menache, (1979) described a procedure in which 
oxalate was precipitated with calcium chloride; the
calcium remaining in the supernatant was determined by 
atomic absorption spectrophotometry. The amount of oxalate 
in the precipitate was then calculated indirectly,
allowing for endogenous urinary calcium, obtained from 
'reference1 samples. The procedure was further optimised 
by Koehl and Abecassis (1976).
(36)
3.2. Colorimetric procedures
For colorimetric estimation of oxalate in urine it 
is necessary to separate the oxalate from interfering 
substances prior to analysis.
Separation has been affected by ion exchange 
chromatography (Dagneux, Ehlhorst and Olthius 1976, 
Olthius et al 1977), by precipitation as the calcium salt 
with calcium sulphate (Hodgkinson and Williams 1972) or 
calcium chloride (Hodgkinson and Zarembski 1961) and by 
extracting the urine with ether (Dempsey et al 1960, 
Hodgkinson and Zarembski 1961). The oxalic acid is then 
reduced to glycolic acid and is further reduced to 
formaldehyde which on addition of chromotropic acid forms 
a violet coloured p-quinoidal compound with a peak 
absorbance at 570 nm. Formaldehyde may also be reacted 
with 2,7, dihydroxynapthalene to give a red compound 
absorbing at 530 nm. This has been suggested as an 
alternative method for the estimation of oxalic acid 
(Calkins 1943, Snell and Snell 1953).
Hausman et al (1956) described a procedure in 
which, after precipitation as the calcium salt with 
calcium chloride, oxalate was decarboxylated to formate 
which then reacted with indole to form
indylindolidinemethane which absorbs at 540 nm. The 
precipitation of oxalate as cerium oxalate and its 
subsequent oxidation by hydrogen peroxide to form a 
brown-coloured compound may also be used (Snell and Snell
-
(37)
1953) .
Indirect colorimetry, in which oxalate reduced the 
colour intensity of the complex formed between ferric ion 
and 7-iodo~8-hydroxyquinoline-5-sulphonic acid or reduced 
the absorbance at 515 nm of the uranyl-4 
(pyridyl-2-azo)-resorcin complex (Neas and Guyon 1972, 
Baadenhuijsen and Jansen 1975, Prenen et al 1983) has been 
described.
3.3. Titration.
The estimation of oxalate by direct titration with 
potassium permanganate after precipitation from urine as 
the calcium salt has been described by Archer et al 
(1957). After an ether extraction and calcium 
precipitation, Powers and Levatin (1944) back titrated an 
excess of potassium permanganate with sodium thiosulphate 
and after subtraction of a reagent blank calculated the 
oxalate concentration.
Cerate titration with nitroferroin as the 
indicator has been applied to the analysis of urinary 
oxalate (Koch and Strong 1969) by the modification of a 
procedure originally proposed for the estimation of 
oxalate in beer (Koch and Strong 1965).
More recently Giterson, Sloof and Schoufer (1970) 
precipitated oxalate from urine as the calcium salt with a 
known quantity of calcium chloride and subsequently 
estimated the calcium remaining in the supernatant by
(38)
titration with EDTA using 'murexide' as an indicator. The 
urinary oxalate was indirectly calculated from this 
calcium estimation after subtraction of a 'blank1
t
estimation of urinary calcium.
3.4. Enzymic methods.
Oxalate decarboxylase (E.C. 4.1.1.2.) and oxalate 
oxidase (E.C. 1.2.3.4.) have both been employed in the
estimation of oxalate in urine. The reaction schemes for 
both enzymes are shown in figure 1.4.
In the oxalate oxidase system, the CO2 
produced has been quantified by following the pH change of 
the system caused by the diffusion of the CO2 into an 
alkaline buffer (Kohlbecker, Richter and Butz 1979, 
Kohlbecker and Butz 1979, Boer, Leersum and Endeman 1984), 
and after immobilisation of the enzyme in an acrylamide 
gel over a CC>2 sensor to form an oxalate electrode 
(Sheldon et al 1983).
The hydrogen peroxide has been quantified 
colorimetrically using a peroxidase (E.C. 1.11.1.7.)
enzyme system to bring about the formation of an indamine 
dye (Sagiura et al 1979, Laker, Hofmann and Meeuse 1980, 
Sagiura et al 1980, Buttery et al 1983, Crider 1983, 
Obzansky and Richardson 1983, Potezny et al 1983) as shown 
in figure 1.5., or by using a catalase (E.C. 1.11.1.6.) 
linked with an NADP-requiring aldehyde dehydrogenase (E.C.
1.2.1.5.) system to produce NADPH (Kohlbecker and Butz
(39)
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1979, Kohlbecker and Butz 1981) as shown in figure 1.6.
In the oxalate decarboxylase system, the CC^ 
evolved has been measured manometrically in Warburg 
systems (Shimazono and Hayaishi 1957, Mayer, Markow and 
Karp 1963, Ribeiro and Elliot 1964), by following the pH 
change of an alkaline buffer (Hallson and Rose 1974 Ackay 
and Rose 1979), by following the change in conductivity of 
a solution of strontium hydroxide (Bishop et al 1982) and 
after immobilisation of the enzyme in an acrylamide gel 
over a CO2 sensor to form an • oxalate electrode 
(Sheldon et al 1983).
The formate has been quantified colorimetrically 
using an NAD-requiring formate dehydrogenase (E.C.
1.2.1.2.) system to produce NADH (Costello, Hatch and 
Bourke 1976, Hatch, Bourke and Costello 1977, Chalmers 
1979, Beutler et al 1980, Yriberri and Posen 1980) as 
shown in figure 1.7.
3.5. Fluorimetric analysis.
The fluorimetric determination of oxalate in urine 
has been described in which the oxalate was first 
extracted with tri-n-butyl phosphate and subsequently 
precipitated as the calcium salt with calcium sulphate. 
The oxalate was then reduced to glyoxylic acid which 
formed a fluorescent complex with resorcinol, probably by 
the formation of a lactone of 2,2',4,4*
tetrahydroxydiphenylacetic acid which had an excitation
(40)
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wavelength of 490 nm and an emission wavelength of 530 nm 
(Zarembski and Hodgkinson 1965a, Zarembski and Hodgkinson 
1965b).
Alternatively, the oxidative power of oxalic acid, 
after precipitation with calcium chloride, has been used 
to reduce cerium (IV) to fluorescent cerium (III) which 
has an excitation wavelength of 260 nm and an emission 
wavelength of 350 nm. (Meola et al 1983).
3.6. Gas chromatographic methods.
Gas chromatography is a separation technique with
which the compounds to be separated are partitioned
between a mobile phase (the carrier gas) and a stationary 
phase (the liquid phase or adsorbent). The difference in
partitioning of the components between the stationary and 
the mobile phase affects the separation.
The requirements for compounds to be analysed by 
gas chromatography are such that they are sufficiently 
volatile at temperatures below 400 °C and will not 
decompose at the working temperatures. If the compound 
itself does not fulfill these criteria, it may be possible 
to synthesise a stable volatile derivative.
The methods described for the analysis of oxalate
all require initial derivatisation and usually some 
separation of the oxalate or its derivative from other 
interfering components of urine.
Columns packed with silicone (Tanaka et al 1980a,
(41)
Tanaka et al 1980b, Moye et al 1981, Moye et al 1983) or 
polyethylene glycol (Di-Corcia et al 1982) stationary 
phases, porous polymer packings (Chambers and Russell 
1972, Charransol et al 1978, Park et al 1980) and
capillary columns (Dosch 1979, Wolthers and Hayer 1982)
have all been utilised in the analysis of oxalate.
Flame ionisation detectors have been used to
detect the diethyl ester (Charransol 1978, Offner and 
Uring 1979) the dimethyl ester (Chambers and Russelll972,
Farrington et al 1979, Park et al 1980, Di-Corcia et al
1982, Yanagawa, Ohkawa and Tada 1982), the dipropyl ester 
(Gelot et al 1979) and the trimethylsilyl derivative
(Tanaka et al 1980a, Tanaka et al 1980b, Wolthers and 
Hayer 1982) using a variety of supports and liquid phases. 
The electron capture detection of the bis-2-chloroethyl 
ester (Tocco et al 1979, Moye et al 1981, Moye et al 1983) 
has also been reported. A capillary gas chromatographic
method using a flame ionisation detector for the
trimethylsilyl derivative has been described by Wolthers
and Hayer (1982) and for the diethyl ester by Dosch
(1979) .
Duggan et al (1979) described a gas 
chromatographic mass spectrometer (GCMS)procedure for the 
analysis of oxalate as the di-n-propyl ester. A known 
amount of [1,2, 13C] oxalate was added to the sample prior 
to precipitation as the calcium salt and subsequent
derivatisation. By the use of selective ion monitoring, 
the ratio of [12C] to [13C] and hence the initial
(42)
concentration of oxalate in the sample was determined.
The time of analysis for each sample has been as 
much as 80 minutes (Gelot et al 1979) but with more 
specific extraction prior to chromatography or by a 
technique known as *backflushing1 the analysis time has 
been reduced to between 6 and 8 minutes ( Di-Corcia et al 
1982, Dosch 1979).
The requirement for the formation of volatile
derivatives, the extraction of either the oxalate or the 
oxalate derivative and the limited number of samples that 
may be run per day, make gas chromatography poorly suited 
for the routine estimation of oxalate.
3.7. High performance liquid chromatography. (HPLC).
HPLC is a separation technique similar to gas 
chromatography in which the compounds to be separated are 
partitioned between a mobile phase (the eluant) and a 
stationary phase (the column packing or column packing 
coating). The degree of partitioning between the
stationary phase and the mobile phase affects the
separation. The use of smaller particle sizes of the 
packing, (eg 5 and 10 urn) results in increased efficiency 
over classical liquid chromatography.
1 Ion-pair1 reversed phase chromatography is a form 
of partition chromatography which may be used to separate 
charged species, and as such may be used as an alternative 
to ion exchange chromatography. Counter ions are added to
(43)
the mobile phase to neutralise the charge of the solute 
ions and thus regulate their retention. The use of 
U.V.-absorbing or fluorescent counter ions may permit more 
convenient detection of the eluted solute and counter ion 
pair than of the solute alone.
Direct chromatography of oxalate using a reversed 
phase octasilyl column with a tetrabutylammonium hydrogen 
sulphate ion pair, which both increases the retention of 
oxalate on the column, and allows detection of the ion 
pair at a wavelength of 220 nm has been described (Libert 
1981 * Larsson, Libert and Asperud 1982) . When the method 
was applied to the analysis of urinary oxalate (Larsson et 
al 1982) initial sample preparation was required and the 
analysis time for each sample was 20 minutes.
Imaoko et al (1983) described a procedure in which 
oxalate, after extraction with tri-n-butyl phosphate, was 
esterified with 9-anthryldiazomethane to form a 
fluorescent derivative which was subsequently
chromatographed on a reversed phase octadecylsilyl column 
and detected fluorometrically. Although the retention time 
for the oxalate derivative was only 15 minutes, the need 
to allow for later eluting endogenous components increased 
the analysis time to 40 minutes per sample. Hughes, Hager 
and Sutton (1982) extracted oxalate with 1,2, 
diaminobenzene to form 2,3, dihydroxyquinoxaline which was 
subsequently chromatographed on a reversed phase octasilyl 
column with ultraviolet detection at 312 nm. A solvent 
program was used which included a gradient elution step to
(44)
rapidly clear the column of later eluting components; this 
reduced the analysis time to 21 minutes.
Anion exchange HPLC with electrochemical detection 
has been described using tetrabutylammonium
tetrafluoroborate ion pair with isocratic elution (Mayer 
et al 1979a, Mayer et al 1979b) and with no ion pair agent 
but with gradient elution (Asper and Schmucki 1979) . Seta
(1980) described an anion exchange procedure utilising 
stopped flow ultraviolet scan detection with gradient 
elution.
3.8. Ion chromatography.
Ion chromatography was first described by Small, 
Stevens and Bauman (1975). It is a form of HPLC which 
utilises a low surface capacity ion exchange 
'chromatographic' or 'separator' column to affect the 
separation coupled with a high capacity ion exchange 
'suppressor' or 'stripper' column to reduce the background 
conductivity of the eluant by ion exchange action and 
therefore allow conductimetric detection of the eluted 
ions.
For oxalate analysis the 'separator' column is a 
low capacity anion exchanger, and the 'stripper' column a 
high capacity cation exchanger (H+ form).
The technique has been applied to the analysis of 
oxalate in unprocessed urine (Mahle and Menon 1982, Dionex 
1982, Menon and Mahle 1983). Although the procedure has
(45)
been claimed to be accurate and precise (Mahle and Menon 
1983) a single sample required 30 minutes analysis time 
and due to the need to regenerate the 'stripper1 column 
after 2.5 hours of use the number of samples that may be 
analysed per day was limited.
3.9. I on speci f ic electrodes.
Ferrel, Blackburn and Vosburgh (1948) described a 
silver - silver oxalate and a mercury - mercurous oxalate 
electrode. The silver oxalate electrode system was further 
investigated by Mathur and Naqui (1968) who observed that 
the electrode system was not sensitive to wide variations 
in either temperature or electrolyte concentration and 
they suggested its use as a reference electrode. As such 
the application of this system to the estimation of 
oxalate was limited.
3.10. Isotachophoresis.
Isotachophoresis is an elecrophoretic technique 
which requires two electrolytes, the 'leading 
electrolyte', which contains an ion with highest 
electrophoretic mobility, and the 'terminating
electrolyte', which contains an ion with the lowest 
electrophoretic mobility in comparison to the intermediate 
mobilities of the sample ions. The theory of 
elecromigration methods of separation has been described
(46)
by Prusik (1979) .
A capillary isotachophoretic procedure for the 
estimation of oxalate in unprocessed urine has been 
described by Tschope, Bremen and Ritz (1981) in which the 
time for each analysis was between 20 and 60 minutes.
3.11. Isotope Dilution.
To overcome the problem of incomplete recovery or 
incomplete derivatisation of oxalate a number of workers
have used isotope dilution techniques.
In the GC/MS method of Duggan et al (1979) a known 
amount of [13 C] labelled oxalate was added to the sample 
and, after derivatisation, the ratio of [12 C] to [13 C] 
was measured by selective ion monitoring and the total 
oxalate in the sample calculated by the dilution of the 
[13 C] .
[14 C] labelled oxalate has been used where the 
total radioactivity added was known and after conversion 
to glycollate (Hockaday et al 1965) or reprecipitation as 
the calcium salt (Gibbs and Watts 1969), the specific
activity of the product was estimated and the total
oxalate content of the sample calculated.
3.12. Discussion.
The majority of the procedures so far described 
were not suited to the routine analysis of urinary
(47)
oxalate. Chromatographic procedures have been shown to be 
limited not only by the length of time required for each 
analysis but also by the need for initial sample
preparation or derivatisation.
Spectrophotometric and oxidometric analyses were 
also restricted by the requirement for sample preparation 
and although recoveries may be monitored by the use of 
labelled oxalate- and isotope dilution, this increases the 
complexity of the procedures.
Ion specific electrodes, although theoretically 
possible have not been applied to the direct estimation of 
oxalate in urine.
Of the procedures outlined in this section, the
use of specific enzymes has attracted the greatest and 
most recent attention in the literature for the rapid and 
specific analysis of oxalate in unprocessed urine.
Table 1.3. shows the performance figures of a 
number of methods of urinary oxalate analysis, as quoted 
by the authors.
The lower limits of the cited reference ranges 
vary from 0 to 352 |umol/d( and the upper limits vary from 
255 - 1020 jumol/d, . This wide variation of reference range
indicates the difficulties that the analysis of oxalate in 
urine has posed.
Methods which claim a lower reference limit of 
less than 100 !umol/d or an upper limit of less than 400
umol/d probably underestimate the oxalate content of
urine, and methods which claim a lower reference limit of
(48)
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over 300 umol/d an<3 an upper reference limit of over 700 
i Urnoi/c3 probably overestimate the urinary oxalate. Nearly 
half of the methods cited in table 1. have reference 
ranges outwith these criteria.
From all of the above considerations, the need for 
an urinary oxalate assay which is simple to perform, 
rapid, precise and accurate is evident.
4. AIMS OF THE PRESENT STUDY.
4.1. Analytical.
In a recent study which compared six methods of 
urinary oxalate estimation, no single technique was found 
to be superior to the others. The methods investigated 
were colorimetric, enzymic, ion chromatographic, high 
performance liquid chromatographic and gas chromatographic 
procedures (Zerwekh et al 1983).
One of the aims of the present study has been to 
develop a procedure which was suitable for the routine 
analysis of a large series of samples.
4.2. Clinical.
The clinical aim of this study was to assess the 
effects of two prophylactic therapies, 300 rag allopurinol 
/ day and 5 mg bendrofluazide / day, on the progress of 
stone forming patients presenting on an out patient basis
(49)
to the Urology Department of the Glasgow Royal Infirmary, 
both clinically by the interpretation of subjects' case 
notes and biochemically by the estimation of blood and 
urinary constituents, including urinary oxalate, before 
and during therapy (table 3.1.).
(50)
CHAPTER 2. METHODS.
1. REFERENCE URINARY OXALATE PROCEDURE.
The reference method of analysis used in this 
study was a colorimetric procedure based on the method 
described by Hodgkinson and Williams (1972), a development 
of two earlier procedures developed in the same laboratory 
(Hodgkinson and Zarembski 1961, Zarembski and Hodgkinson 
1965) with some modifications suggested later by Husdan et 
al (1976). The method had been used in previous studies in 
the Urology Department (Scott et al 1978a, Scott et al 
1978b).
The method relies on the separation of oxalate 
from interfering substances in urine by co-precipitation 
of oxalate from urine with calcium sulphate at pH 7. 
Subsequent reduction of the oxalate to glycollate by 
nascent hydrogen is brought about by boiling the 
precipitate with dilute sulphuric acid and a zinc pellet. 
The glycolic acid is then reduced to formaldehyde, which 
is believed to form a violet coloured p-quinoidal compound 
with chromotropic acid (Feigl 1966), by boiling with 
chromotropic acid and concentrated sulphuric acid. A 
similar reaction procedure has been described by Snell and 
Snell (1953). The probable reaction scheme is described in 
figure 2.1.
(51)
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1.1. Sample Collection.
Twenty four hour urine samples were collected 
directly into polythene bottles containing 5 ml of 
concentrated hydrochloric acid which lowers the pH of the 
urine to between 1 and 3, with the object of preventing 
the oxalate precipitating before analysis. The solubility 
of calcium oxalate in aqueous solution has been shown to 
increase with increased acid concentration (Hodgkinson
1981) .
The volumes of the urine collections were measured 
on receipt by weighing. 20 ml aliquots from the well mixed 
collections were taken for the analysis of calcium,
magnesium, creatinine, urate and oxalate.
The aliquots for oxalate estimation were stored at 
+4 C until analysis, which was generally performed within 
one week of receipt. After analysis, the aliquots were 
stored at -20 °C to preserve the samples. ;
1.2. Materials.
Unless otherwise stated, all materials were of
AnalaR grade, supplied by B.D.H. (England).
Centrifuge tubes
M.S.E. straight walled 112 x 28 x 20 mm internal diameter, 
scored at 20 ml level with a diamond.
Mean volume = 19. 98 ml <CV =7. 32 V  n = 42) .
(52)
2. 2l chromotropic acid
1 g 4,5-dihydroxynapthalene 2,7-disulphonic acid (Sigma 
Chemical Company) dissolved in 100 ml distilled water, 
stored at +4 C. Prepared fresh each week.
Stock standard oxalate. 60 mM.
2.7636 g Potassium Oxalate; K2C2°4*H2° made up to 250
ml with distilled water, stored at +4 C. Prepared fresh 
each month.
Working oxalate standard. 600 uM
1 ml of the stock standard oxalate diluted to 100 ml with 
distilled water. Prepared for each assay.
Zinc pellets
3.2 mm diameter zinc wire (Pierce and Warriner, England)
cut into 5 mm lengths (300 mg) washed immediately before
use in fresh 10 M nitric acid and rinsed in distilled
water.
Calcium sulphate
Saturated aqueous solution prepared as required.
10 M nitric acid
158 ml of 70 % hn03 (m.wt.= 63.01) solution of
specific gravity 1.42 made up to 250 ml with distilled 
water.
(53)
0.2 M sodium hydroxide
2 g NaOH (m.wt.=40.0) dissolved in 250 ml distilled water. 
0.2 M hydrochloric acid
4.4 ml of 35 % HC1 (m.wt.= 36.46) solution of specific
gravity 1.18 made up to 250 ml with distilled water.
Concentrated sulphuric acid
98 % of specific gravity 1.84.
5 M sulphuric acid
269 ml of concentrated sulphuric acid made up to 1 litre
with distilled water.
2_ M sulphuric acid
400 ml of 5 M sulphuric acid made up to 1 litre with
distilled water.
1 M sulphuric acid
500 ml of 2 M sulphuric acid made up to 1 litre with
distilled water.
Ethanol
Absolute alcohol CoHc0H. 99.7 %./L D
1.3. Procedure.
To 1.5 ml of urine or quality control samples, in
(54)
duplicate, was added 0.5 ml of distilled water. The pH was 
then adjusted to pH 7 (6.8 to 7.2) by the dropwise
addition of 0.2 M NaOH or 0.2 M HC1 as necessary, the pH 
being monitored using a suitable pH electrode. 2 ml of 
saturated calcium sulphate was added, followed by 14 ml of 
ethanol. After mixing, the tubes were left at room 
temperature overnight. The samples were then spun at 1200 g 
for 10 minutes, the supernatant solution carefully 
decanted, and the tubes allowed to drain, in an inverted 
position, for a few minutes. The precipitate was then 
taken up in 2 ml of 1 M sulphuric acid.
Six standards were prepared by adding 0, 0.125, 
0.25, 0.5, 0.75 and 1.0 ml of the 600 uM working oxalate 
standard, to separate tubes, and making the final volume 
to 1 ml with distilled water. To each of these tubes was 
added 1 ml of 2 M sulphuric acid to provide standard
values of 0, 50, 100, 200, 300, and 400 uM oxalate.
A freshly cleaned zinc pellet was then added to 
each tube, and the tubes placed in a boiling water bath, 
in a fume cupboard, and evaporated to dryness.
After being allowed to cool, the zinc pellets were 
removed and washed with 0.5 ml of 1 % chromotropic acid. 
(This was more easily achieved if the tube was clamped
horizontally in a retort stand, and the zinc pellet drawn
towards the mouth of the tube with . a sealed and bent 
pasteur pipette, where it was washed with the chromotropic 
acid, and the washings passed into the tube, before final 
removal of the pellet.)
(55)
5 ml of concentrated sulphuric acid was then
carefully added to each tube, with mixing, and the tubes
were replaced in the boiling water bath for a further 30 
minutes.
The tubes were removed and allowed to cool. 5 M 
sulphuric acid was added to a final volume of 20 ml in
each tube and, after mixing, the absorbance was measured 
at 570 nm, using the zero standard as a blank.
The concentration of oxalate in the samples and 
quality controls was then calculated from the regression 
equation of the six standards.
1.4. pH of collected urine samples.
The pHs of 30 urine specimens, chosen at random, 
were measured. The mean value was 2.46 0.46) and the
coefficient of variation was 18.8 %. The pH ranged from
1.70 to 3.80. ;
1.5. Linearity.
Aqueous standards up to 4 mmol/1 were prepared. 
The results are shown in figure 2.2. The method was shown 
to be linear to a urinary oxalate concentration of 1500 
umol/1. No. specimens were found to be above this level.
(56)

1.6. Precision.
1.6.1. Within run precision.
The within run precision was estimated using five 
urine specimens. The results are shown in table 2.1.
The coefficient of variation ranged from 2.13 to 
9.62 %, and the mean values of the urine samples from 49.4
to 506 umol/1.
1.6.2. Between run precision.
Five urine specimens have been used as quality 
control material, prepared as shown in table 2.2., and to 
estimate the between run precision. The results are shown' 
in table 2.3 and figure 2.3.
Sample number 4 was, in effect, an external 
quality control sample, and the target range for oxalate 
suggested by the manufacturers using a gas chromatographic 
method was 122 to 278 umol/1, and by an atomic absorbtion 
method 156 to 222 umol/1 (Lyphocheck 1882). A mean value 
of 222 umol/1 ( + 26.3) was found in this study.
The wide target range, quoted by the manufacturer 
for the gas chromatographic method, which was considerably 
different from the range quoted for the atomic absorption 
method limits the usefulness of this sample as an external 
quality control for any other method of analysis. This 
also underlines the overall problem of urinary oxalate
(57)
Table 2.1. Within run precision of the reference
procedure.
SAMPLE n MEAN(umol/1) S.D. C.V.%
1 8 49.4 4.75 9.62
2 9 179 10.8 6.04
3 8 180 3.83 2.13
4 9 374 17.9 4.79
5 8 506 14.7 2.90
Table 2.2. Preparation of quality control samples.
SAMPLE PREPARATION
specimen aliquoted (5ml) stored at -20C 
to use.
Pooled urine specimen, aliquoted (5ml) and 
lyophilised. Stored -20C. Reconstituted with 5ml 
distilled water prior to use.
1&2 Pooled urine 
Thawed prior
4 'Lyphocheck Quantitative Control Urine 1 (Human)'.
A lyophilised control urine. Supplied by Bio-Rad 
Laboratories (England) from Environmental Chemical
Table 2.3. Between run precision of the reference procedure.
SAMPLE n MEAN (umol /l) S.D. C.V.%
1 34 99.2 16.6 16.8
2 18 131 12.1 9.25
3 30 177 19.2 10.9
4 26 222 26.3 11.9
5 12 341 25.4 7.46
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analysis of accuracy and precision.
The coefficient of variation ranged from 9.25 to
16.8 % for the quality control specimens, and the mean
values ranged from 99.3 to 345 umol/1.
The quality control chart for the 2 year period of 
April 1982 to April 1984 is shown in figure 2.3.
1.7. Recovery.
1.7.1. Recovery from aqueous solution.
The recovery of oxalate from aqueous samples was 
estimated at five levels on a between run basis. The 
results are shown in table 2.4.
Overall, for 50 samples, the recovery was 103 % (
± 9.45) .
1.7.2. Recovery from urine.
A number of separate urine specimens were ’spiked' 
with aqueous oxalate at 3 levels, and the recoveries shown 
in table 2.5. were found.
Overall, for the 37 urine samples, the recovery 
ranged from 62.0 to 91.5 % with a mean value of 75.4 % ( _+ 
7.91).
(58)
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Table 2.5. Oxalate recovery from urine in the reference
procedure.
SPIKE (umol/1) n 7 X RECOVERY%• C.V.%
100 5 70.9 ' 8.56
200 16 77.4 11.1
300 16 74.9 10.1
1.7.3. Sample dilution.
The effect of sample dilution was investigated. A 
single urine specimen was diluted with distilled water and 
assayed 6 times at the following dilutions: undiluted, 1
in 2, and 1 in 5. The results are shown in table 2.6.
The mean recovery for all 18 estimations was 105 %
( + 11.1).
1.8. Interferences.
Five potential precursors of oxalate were examined 
at levels that might be expected to occur in urine. A 
sixth component, glucose, was examined at a level which 
might be expected to occur in the urine from a poorly 
controlled diabetic subject, corresponding to between +++ 
(55 mM) and ++++ (>=111 mM) on Ames Multistix (Miles 
Laboratories, England). The mean recoveries and the 
results of paired t-tests for 5 urines are shown in table
2.7.
The only significant interference found was due to
glucose, which produced a positive interference (P< 0.01).
1.9. Reference range.
The urinary oxalate excretion of 20 apparently 
healthy, non fasting adults was found to range from 191 to 
454 umol/volume with a mean value of 318 umol/volume ( +
(59)
Table 2.6. Effect of sample dilution in the reference
procedure.
DILUTION X  CONCENTRATION(uM) S.D. RECOVERY %
Undiluted 85.7 12.4 100
1 in 2 41.9 5.16 97.8
1 in 5 20.2 3.63 118
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68.2).
1.10. Discussion.
Hodgkinson (1981) has reported errors in the 
determination of urinary oxalate due to sampling errors 
caused by the variable precipitation of oxalate, related 
to pH, and advised that the pH of the urine should be 
lowered to between 1.6 and 1.8, in order to minimise these 
errors.
These errors were shown to occur in urine samples 
which were taken from the upper layers of 24 hour urine 
specimens which were agitated and subsequently allowed to 
stand. At pH 3.0 the initial loss of oxalate was only 3 % 
per minute.
The mean pH value of a randomly chosen group of 
urine samples in this study was 2.46 ( _+ 0.46), and it was 
felt that the additional step of adding sufficient acid to 
bring the pH of the urine down to the advised level was 
not justified as the volume of acid required in some 
specimens was excessive, leading to sample dilution; 
Hodgkinson (1981)admits that,these sampling errors may be 
reduced simply by thorough mixing.
In this study, the reference range for urinary 
oxalate was found to be 191 to 454 umol/volume, which is 
in agreement with that found by Hodgkinson and Williams 
(1972) of 189 to 478 umol/volume.
The within run precision (C.V.) ranged from 2.13
(60)
to 9.62 % over a concentration range of 49.4 to 506
umol/1, and the between run precision (C.V.) from 7.46 to
16.8 % over a concentration range of 99.3 to 341 umol/1.
Recovery from aqueous solution averaged 103 % ( +. 
9.45) and from urine, 75.4 % (+_ 7.91) , with a range in 
urine of 62.0 to 91.5 %. This urinary recovery was lower 
than that found by Hodgkinson and Williams (1972), of a 
mean value of 85.6 % and a range of 75 to 98 %. These
higher recoveries were obtained from an oxalate 'spike* of 
555 uM, whereas the 'spikes' used in this study ranged 
from 100 to 300 uM, which produced levels that were more 
likely to occur in urine specimens.
The effect of sample dilution was minimal, until a 
dilution factor of 1 in 5. By this stage, the lowest 
standard was over twice the concentration of the samples 
measured.
Of the substances investigated, only glucose 
caused a significant, positive, interference with the 
assay. This was found by Hodgkinson and Williams (1972), 
and has also been shown to occur in the estimation of 
formaldehyde by chromotropic acid (Pippenger et al 1983).
2.DEVELOPMENT OF ENZYMIC URINARY OXALATE PROCEDURE.
The method developed in this study was based on 
the double enzyme system using oxalate decarboxylase and 
NAD~requiring formate dehydrogenase, initially described 
by Beutler et al (1980) and later presented as provisional
(61)
working instructions for a U.V. method for the 
determination of oxalate in urine by Boehringer (1982). In 
this method, oxalate was converted to formate and CO2 
at pH 5 by oxalate decarboxylase. The formate formed was 
subsequently converted to bicarbonate at pH 7.5 by formate 
dehydrogenase with the production of NADH from NAD. The 
increase in optical density at 340 nm was proportional to 
the amount of oxalate present at the start, after 
subtraction of any increase in optical density due to 
endogenous formate in the sample by using an appropriate 
sample blank. The overall reaction scheme is shown in 
figure 2.4.
2.1. Materials.
All materials were of AnalaR grade, supplied by 
B.D.H. (England), unless otherwise stated.
Cuvettes
Sarsted (W. Germany) No. 67.741. 1 cm path length.
Micro cuvettes
Sarsted (W. Germany) No. 67.742. 1 cm path length.
Assay tubes
Sarsted (W. Germany) No. 55.484. 3.5 ml, 55 x 12 mm.
(62)
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Oxalate decarboxylase
Boehringer Corporation Ltd (BCL) London. From Aspergillus 
niger . 40 U per ml.
Formate dehydrogenase
BCL (London) from yeast. 0.4 U per mg of lyophylisate.
NAD
BCL (London). Crystallised B-nicotinamide-adenine
dinucleotide as the monolithium salt. 'NAD-Li'. 21^0 ■ 
(m.wt.=705.4).
50 mM NAD solution
420 mg NAD dissolved in 12 ml distilled water.
Pyrazole
Sigma Chemical Company, England. NO.P2646 (m.wt. = 68.1). 
100 mM stock standard oxalate
9.212 g potassium oxalate (m.wt. = 184.24) dissolved in 
500 ml distilled water, stored at +4 C. Prepared each 
month.
100 mM stock standard formate
6.801 g sodium formate (m.wt. = 68.01) dissolved in 1
litre distilled water. Prepared each month.
(63)
500 uM working oxalate standard
0.5 ml of stock standard oxalate made to 100 ml with 
distilled water. Prepared each day.
Buffer 1. (pH 5.0)
0.13 M Na2HP0^ /0.07M citric acid.
18.5 g disodium hydrogen orthophosphate dihydrate (m.wt. = 
177.99) and 14.7 g citric acid monohydrate (m.wt. = 
210.14) dissolved in 950 ml distilled water, adjusted to 
pH 5.0 with 5 M NaOH or 1 M orthophosphoric acid as 
required. Made up to 1 litre with distilled water.
Buffer 2. (pH 9.5)
0.15 M NaoHP0 .2 4
21.2 g disodium hydrogen orthophsphate monohydrate 
dissolved in 950 ml distilled water, adjusted to pH 9.5 
with 5 M NaOH or 1 M orthophosphoric acid as required. 200 
mg pyrazole added and made to 1 litre with distilled 
water •
Formate dehydrogenase solution
80 U formate dehydrogenase dissolved in 1 ml distilled 
water.
EDTA
Ethylene diaminetetra-acetic acid disodium salt (m.wt. = 
372.24).
(64)
2.2. Instrumentation.
A Union Carbide CentrifiChem system 400 analyser 
(Union Carbide Corporation, New York) was used for this 
assay. It was a centrifugal spectrophotometric analyser 
and data processor, capable of processing up to 30 samples 
simultaneously.
The Teflon transfer disc had 30 radial cavities, 
each contoured to form two separate wells for reagent and 
sample, as shown in figure 2.5., and was re-useable.
When the loaded transfer disc was placed in the 
environmentally controlled rotor of the analyser and spun, 
the reagent and sample were mixed and transferred from the 
disc, along the transfer channel, to corresponding optical 
cuvettes in the rotor and held there by centrifugal force.
The optical system of the analyser was such that 
absorbance values for each of the cuvettes were obtained 
as the rotor spun. The absorbance changes were monitored 
visually on a cathode ray tube on the front of the 
analyser, as shown in figure 2.6.
The data processor had two 1 channels’ that stored 
absorbance values at one specified time, T0, and at any 
other specified time, DT, and the processor calculated 
results based on the difference between these two values 
for each cuvette.
The reaction conditions were preset before an 
analysis, on the front of the analyser. These parameters 
were temperature, wavelength, 'T01, 'DT1, 'abnormal
(65)
Reagent Sample
Well Well
Cross section
Plan
FIGURE 2.5. CROSS SECTIONAL DIAGRAM AND PLAN PHOTOGRAPH 
OF THE CENTRIFICHEM TRANSFER DISC.
FIGURE 2.6. CENTRIFICHEM SYSTEM 400 ANALYSER
absorbance’, 'blank', 'test mode', 'print out' , ' standard 
value','number of prints', and 'test code'.
At the completion of a test, the transfer disc and 
the cuvettes were cleaned by initiating the 'clear' cycle.
For 'hold blank' analyses, it was necessary to 
process on the analyser a transfer disc loaded only with 
water. The values of the 'T0' data channel of the 
processor were then arbitrarily fixed.
The other basic component of the CentrifiChem 400 
system was a pipettor. This allowed automated preparation 
of the transfer disc with pre-programmed amounts of 
sample, diluent and reagent. The reagent volume was set at 
either 250 or 350 ul and the sample volume was variable 
between 0 and 50 ul and the diluent volume between 0 and 
55 ul, in steps of 1 ul.
2.3. Basic Aassay procedure.
To a series of 1 cm. cuvettes was added 200 ul of 
sample and 200 ul of buffer I. To each 'test' cuvette was 
added 20 ul of oxalate decarboxylase. The cuvettes were 
mixed and allowed to stand at room temperature for 20 
minutes. To each cuvette was then added 1.0 ml of buffer 
II and 0.5 ml of 50 mM NAD solution. To each cuvette 
assigned as a 'test' was added 1.0 ml of distilled water, 
and to each cuvette assigned as a 'blank' 1.02 ml of 
distilled water. The cuvettes were mixed, and after 2 
minutes the optical density at 340 nm was read (El).
(66)
50 ul of the formate dehydrogenase solution was 
then added, the cuvettes mixed, and allowed to stand at 
room temperature for 20 minutes, after which the optical 
density at 340 nm was read (E2).
The optical density difference for each cuvette 
was calculated from E2-E1, and the difference due to 
oxalate, DE, was calculated by subtracting the optical 
density difference of the 'blank' cuvette from that of the 
coresponding 'test' cuvette.
The oxalate concentration in the sample was then 
calculated from the following equation:
. V
c = ------ ----x DE
E.d,v. :• - 1 
' ■
where; c = concentration 
V = total volume 
v = sample volume 
d = light path
E = extinction coefficient of NADH 
DE= absorbance due to oxalate
Under the above conditions;
c = 2.38.DE mmol/1
(67)
This procedure was not evaluated, but used as a 
basis for the development of an automated micro-enzymatic 
method for urinary oxalate analysis.
It was both expensive, due to the volumes of 
reagent required, and complicated, due to the number of 
pipetting steps required for each sample.
A simpler and cheaper procedure was envisaged by 
reducing the reagent and sample volumes, the combination 
of reagents to allow single step reagent addition, and by 
some degree of automation of the formate dehydrogenase 
reaction step.
2.4. Reduction in sample and reagent volumes.
A single aqueous oxalate sample was analysed using 
the sample and reagent volumes shown in table 2.8.
Assays 1 and 2 were carried out in 1 cm disposable 
optical cuvettes and assay 3 was carried out in 1 cm 
disposable micro cuvettes.
The results are shown in table 2.9.
A single 24 hour urine sample was collected into a 
polythene bottle containing 5 ml of concentrated HC1, and 
immediately before assay, an aliquot was adjusted to pH 5 
with 5 M NaOH or 1 M orthophosphoric acid as required.
The sample was assayed for oxalate 4 times as per 
assay 3 and a mean value of 124 uM ( + 6.19%) was found. 
The recovery of aqueous oxalate added to final
(68)
Table 2.8. Reagent and sample volumes (in ul) of the enzymic
procedure.
Reagent Assay
1 2 3
Buffer I 200 100 50
Sample 200 100 50
Decarboxylase 20 10 5
Buffer II. 1000 500 250
NAD solution 500 250 100
Water 1000 500 250
Formate Dehydrogenase 50 25 10
Total Volume 2970 1485 715
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concentrations of +100, +200 and +300 umol/1 in urine was
75.3, 86.8 and 78.5 % respectively. By comparison the
recovery from the aqueous standards of 50, 100 and 200 uM 
oxalate was 97.9, 97.0 and 97.8 % respectively.
This showed that the scaling down of the method 
was at least feasible, and at this stage, the recovery of 
oxalate from urine was similar to that found using the 
reference method, but still well below 100 %.
2.5. Reagent combination.
In order to reduce the number of pipetting steps 
required in the assay, the reagents were combined, as far
as possible.
For the first reaction, a single buffered oxalate 
decarboxylase reagent was prepared containing 4 units of 
oxalate decarboxylase per ml of buffer I. Addition of 50 
ul of this reagent to 50 ul of sample produced the same
ratio of sample volume to enzyme units, and a similar 
sample volume to total reaction volume ratio as in the 
basic assay procedure. For sample blanks, 50 ul of buffer
I was used.
Due to the constraints of the reagent volumes 
available on the CentrifiChem 400 pipettor, and with a 
view to automation of the second reaction procedure; the 
formate dehydrogenase / NAD reagent volume was restricted 
to 250 ul only. This represented a reduction in volume by 
a factor of 10.2 in comparison to the basic assay
(69)
procedure. '
A similar reduction in the sample size for the 
first reaction resulted in a final volume of 41.2 ul. A 
more convenient volume of 40 ul was selected.
The formate dehydrogenase / NAD reagent was 
prepared by adding 80 units of lyophylised formate 
dehydrogenase and 350 mg of NAD to 20 ml of buffer II. The 
final volume was made up to 50 ml with distilled water.
The sample volume to total reaction volume, the 
sample volume to enzyme units, and the sample volume to 
NAD ratios were 0.14, 0.1 ml/unit and 16 ul/umol
respectively, which were similar to the ratios in the 
basic assay procedure.
2.6. Initial CentrifiChem procedure.
The oxalate decarboxylase and formate
dehydrogenase reagents were prepared as described in 
section 2.5., and the following method was developed.
2.6.1. Method 1.
To a series of assay tubes was added 50ul of 
sample or standard. To each tube assigned as a 'test' was 
added 50 ul of the oxalate decarboxylase reagent, and to 
each tube assigned as a 'blank', 50 ul of buffer I. The 
tubes were mixed and allowed to stand at room temperature 
for 20 minutes, after which the contents of each tube were
(70)
transferred to the corresponding sample cup of the 
CentrifiChem 400 pipettor. The reagent boat of the
pipettor was filled with the formate dehydrogenase
reagent.
The following parameters were set on the pipettor; 
reagent volume = 250 ul; sample volume = 40 ul; sample and 
diluent volume = 9 0  ul. The pipetting cycle was then 
started.
Once the transfer disc had been prepared, the 
following parameters were loaded into the CentrifiChem 400 
microprocessor:
Temperature 30 °
Filter 340 nm
T0 3 seconds
DT 2.5 minutes
Abnormal absorbance 2.0 U
Blank AUTO
Test mode TERM
Print out ABSORBANCE
Standard value 0000
Number of prints 9
Test code 00
The loaded transfer disc was then placed in the
analyser rotor and the analysis performed.
The change in absorbance due to oxalate was then
calculated by subtracting the change in absorbance of the 
'blank' cuvettes from the change in absorbance of the
(71)
coresponding 'test' cuvettes, after 15 minutes, and the 
oxalate concentration calculated from the regression 
equation of as series of standards.
2.6.2. Investigation of method 1.
As it was the second reaction step which was being 
investigated, aqueous formate standards rather than 
aqueous oxalate standards were prepared in order to reduce 
the reagent ie. oxalate decarboxylase requirement at this 
stage. The inclusion of a standard curve was considered 
appropriate, as this avoided any errors that might have 
occurred due to differences in absolute volumes in each 
sample if the results were calculated from the molar 
extinction value of NADH.
2.6.3. Estimation of formate standards. .
A series of aqueous formate standards from 0 to 
2060 uM were prepared and assayed as per method 1.
As the absorbance values measured on the 
CentrifiChem were printed every 2.5 minutes (DT), the 
optical density against time for the four standards 294, 
735, 1470, and 2060 uM was plotted. These results are
displayed in figure 2.7., and show that the reaction is 
complete within 15 minutes. For this reason the print out 
at 15 minutes was used for all further calculations.
The absorbance values at 15 minutes versus the
(72)
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standard concentration are shown in figure 2.8.
These results show that for aqueous formate 
standards the method was linear to at least 2060 uM, and 
when the formate concentration was calculated from the 
extinction coefficient of NADH the mean recovery was found 
to be 95.8 % ( + 4.11).
A number of standards were assayed to determine if 
there was any sample carry-over between high and low 
samples in the pipettor system. The results are shown in 
figure 2.9. From these results sample carry-over was 
evident.
A higher sample to diluent ratio of 35 ul sample 
to 55 ul diluent was investigated. The results, shown in 
figure 2.10., show that even at this increased sample to 
diluent ratio, sample carry-over was still occurring.
To overcome this problem, a transfer disc was 
prepared manually by the addition of 50 ul of the reagent 
mixture into the sample well of the disc, without diluent, 
and 250 ul of the formate dehydrogenase reagent to the 
reagent well. The results are shown in figure 2.11., and 
as was expected, no evidence of sample carry-over was 
noted.
2.7. Modified CentrifiChem procedure.
From the investigations in section 2.6. the 
following modifications to the initial CentrifiChem 
procedure were instigated. '
(73)
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2.7.1. Modi f ication of procedure.
In order to increase the sensitivity of the assay, 
the sample volume for the oxalate decarboxylase reaction 
was increased from 50 to 100 u l , and the oxalate
decarboxylase reagent volume maintained at 50 u l . To 
compensate for the increased amount of oxalate present in 
the reaction mixture, the incubation time was increased
from 20 minutes to 1 hour. *
The reagent and sample volumes for the formate 
dehydrogenase reaction were altered to 300 ul and 50 ul 
respectively since these volumes allow a more convenient 
manual preparation of the transfer disc, while maintaining 
a similar sample to total volume ratio.
In order to further reduce the cost of the assay, 
the concentrations of the formate dehydrogenase and the
NAD in the formate dehydrogenase / NAD reagent were
reduced.
The formate dehydrogenase reagent in section 2.5. 
was used such that 0.4 units of enzyme was added per 
cuvette. A combination of 8 units of formate
dehydrogenase, 20 mg NAD, 3.8 ml buffer II and 5.6 ml
distilled water produced a reagent that when used at a 
rate of 300 ul per sample delivered 0.31 units of enzyme
per sample. To compensate for the reduced enzyme
concentration, the incubation time on the CentrifiChem
analyser was increased to 35 minutes. In this instance,
(74)
the time interval (DT) on the analyser was set to 5 
minutes.
As the initial rate of reaction of the formate 
dehydrogenase reaction appeared to be rapid (figure 2.7.) , 
the change in absorbance that occurred in the first few 
seconds of the reaction (T0) was not measured and was not 
included in the measurement of the end-point absorbances. 
To overcome this, a separate 'hold blank1 value was loaded 
into the CentrifiChem data processor as described in 
section 2.2., such that the end-point absorbances were 
compared to this preset value. As the initial time 
inteval, T0, was no longer critical, it was increased to 5 
seconds to ensure that the mixing of the reactants v/as
complete before the first absorbance value was measured.
2.7.2. Investigation of modified procedure.
As the absorbance values measured on the
CentrifiChem were printed every 5 minutes, a series of
aqueous formate standards were run as per the modified
procedure, and the absorbance values plotted against time. 
The results, shown in figure 2.12., confirmed that the 
formate dehydrogenase reaction was effectively complete
within 35 minutes; the absorbance values at 35 minutes
were used for all further calculations.
A linear response of absorbance to aqueous oxalate 
concentration was found (figure 2.13.).
Initial incubation periods for the oxalate
(75)
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decarboxylase reaction of 0.5, 1 and 2 hours were
investigated using two urine samples.
Immediately prior to estimation, an aliquot of the 
acidified 24 hour urine collection was brought to pH 5 by 
the addition of 5 M NaOH or 1 M orthophosphoric acid as 
required. The results, shown in table 2.10., show that the 
oxalate decarboxylase reaction appeared to be incomplete 
at 30 minutes, but that it was complete within 1 hour.
At this stage, the recovery of a 300 umol/1
aqueous oxalate ’spike' to 4 * urine samples was
investigated. The results are shown in table 2.11.
The mean recovery was only 72 % (+^15.6).
A number of studies, using the enzyme oxalate
decarboxylase for the estimation of urinary oxalate, have 
included in the reagents ethylenediaminetetra-acetic acid 
(EDTA) (Mayer et al 1963, Rebeiro and Elliot 1964, 
Costello and Hatch 1976, Hatch et al 1977, Yriberi and
Possen 1980), although only Mayer (1963) has noted that 
the EDTA increased the recovery of added oxalate.
Mayer (1963) suggested that the EDTA acted upon
some enzyme inhibitor present in the urine, such as
interference from anions, mainly phosphates, or that it
. 2+ may compete with the oxalate for cations such as Ca
2+ . 
or Mg m  the urine thus increasing the soluble
oxalate fraction and improving the recovery.
• To this end, to 5 ml aliquots of acidified 24 hour 
urine samples was added 150mg of disodium EDTA. The pH of 
the urines was then adjusted to 5 as described earlier and
(76)
Table 2.10.Effect of incubation time on oxalate estimation.
SAMPLE INCUBATION TIME
0. 5h lh 2h
1 122uM 146uM 147uM
2 172uM 195uM 191uM
Table 2.11.Oxalate recovery from urine in the enzymic
procedure.
SAMPLE SPIKE (uM) RECOVERY%
1 300 81.'3
2 300 48.7
3 300 76.0
4 300 81.3
the samples were placed in a 60 °C water bath for 20 
minutes to ensure dissolution of the EDTA.
Four urine specimens were 'spiked' with aqueous 
oxalate, prepared in the above manner and then assayed as 
per the modified procedure. The results are shown in table 
2.12.
The mean recovery was 100 % ( _+ 6.8).
2.8. Further modifications.
From the limited investigations in section 2.7. 
the following modifications were made to the procedure 
before a detailed evaluation of the technique was 
performed.
2.8.1. Sample preparation.
The addition of EDTA to the urine sample prior to 
estimation was found to be necessary to ensure complete 
recovery of oxalate.
2 .8 .2 . Two point standard curve.
As the method was shown to be linear, a two point 
standard curve with zero and 500 uM calibrators was 
required. The data processor of the CentrifiChem analyser 
was then be used to calculate and print out the oxalate 
concentrations in each cuvette by reference to these two
(77)
Table 2.12.Recovery of oxalate from urine.Effect of EDTA in
the enzymic procedure.
SAMPLE SPIKE(umol / 1) RECOVERY%
1 500 110
2 50 94.6
3 500 99.7
4 50 96.7
values.
2.9. Discussion.
The development of an automated micro-enzymic 
method of urinary oxalate analysis has been described.
For a single urinary oxalate analysis, consisting 
of a 'test' and a 'blank' estimation, an 88 % reduction in 
enzyme consumption and a 38 % reduction in the number of 
separate pipetting steps has been achieved.
As the formate dehydrogenase reaction has been 
adapted to run on the CentrifiChem 400 analyser, the need 
for 6 separate optical density measurements has been 
reduced and entirely automated, although the incubation 
times with both enzymes have been increased.
The overall procedure and the evaluation of the 
assay is described in section 3.
3.EVALUATION OF THE ENZYMIC URINARY OXALATE PROCEDURE.
The principle of this method, and the details of 
the instrumentation have been described in section 2. This 
section is concerned with the evaluation of the assay.
3.1. Materials.
All materials were of AnalaR grade, supplied by 
B.D.H. (England), unless otherwise stated.
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Assay tubes
Sarsted (W. Germany) No. 55.484..3.5 ml, 55 x 12 mm.
Oxalate decarboxylase
Boehringer Corporation Ltd (BCL) London. From Aspergillus 
niger . 40 U per ml
Formate dehydrogenase
BCL (London) from yeast. 0.4 U per mg*of lyophilisate.
NAD ' ‘
BCL (London). Crystallised B-nicotinamide-adenine
dinucleotide as the monolithium salt. NAD-Li^F^O 
(m.wt. = 705.4).
Pyrazole
Sigma Chemical Company, England. NO.P2646 (m.wt. = 68.1). 
100 mM Stock standard oxalate
9.212 g potassium oxalate (m.wt. = 184.24) dissolved in 
500 ml distilled water, stored at +4 °C. Prepared each 
month.
500 uM Working oxalate standard
0.5 ml of stock standard oxalate made to 100 ml with 
distilled water. Prepared each day.
(79)
Buffer 1. (pH 5.0)
0.13 M Na2HP0  ^ /0.07 M citric acid.
18.5 g disodium hydrogen orthophosphate dihydrate (m.wt. =
177.99) and 14.7 g citric acid monohydrate (m.wt. -
210.14) dissolved in 950 ml distilled water, adjusted to
pH 5.0 with 5 M NaOH and 1 M orthophosphoric acid as
required. Made up to 1 litre with distilled water.
Buffer 2. (pH 9.5)
0.15 M NaoHP0.2 ... 4
21.2 g disodium hydrogen orthophsphate dihydrate (m.wt. =
177.99) dissolved in 950 ml distilled water, adjusted to
pH 9.5 with 5 M NaOH or 1 M orthophosphoric acid as
required. 200 mg pyrazole added and made to 1 litre with 
distilled water.
Working oxalate decarboxylase
100 ul oxalate decarboxylase (40 U/ml) mixed with 900 ul 
buffer 1 (pH 5.0). Prepared immediately before use.
Working formate dehydrogenase
8 U formate dehydrogenase, 40 mg NAD, 3.8 ml buffer 2, and 
5.6 ml distilled water. Prepared 1 hour before use and 
allowed to stand at room temperature to ensure dissolution 
of the NAD.
EDTA
Ethylene diaminetetra-acetic acid disodium salt (m.wt. =
(80)
372.24)
3.2. Sample collection.
24 hour urine samples were collected as previously 
described in section 1.2. Immediately prior to assay, a 5 
ml aliquot of the urine sample was brought to pH 5 by the
dropwise addition of 5 M NaOH or 1 M orthophosphoric acid
as required, after addition of 150 mg of EDTA. The samples 
were then placed in a water bath at 60 C for 20 minutes.
3.3. Procedure. '
To a series of assay tubes was added 100 ul of the 
appropriate standard, quality control, or sample. To each 
tube assigned as a 'blank' was added 50 ul of buffer 1, 
and to each assigned as a 'test', 50 ul of the working 
oxalate decarboxylase. The quantity of working oxalate 
decarboxylase prepared in section 3.1. was sufficient for 
one batch of zero and 500 uM standards, 2 quality control 
urines and 11 patient urines plus blanks. The tubes were 
vortex mixed and allowed to stand at room temperature for 
60 minutes. A transfer disc for the CentrifiChem 400
(Union Carbide Corporation, New York) was loaded manually 
by pipetting 50 ul of the reaction mixture from each
numbered tube into the corresponding 'sample' position of 
the disc. 300 ul of the working formate dehydrogenase was 
then added to each corresponding 'reagent' position. 300
(81)
ul of distilled water was placed in reagent position 
'zero' and if less than eleven patient samples were being
estimated, to the remaining unoccupied reagent positions.
The quantity of working formate dehydrogenase prepared in 
section 3.1. was sufficient for one complete transfer
disc.
A 'water blank1 was then loaded into the
CentrifiChem using the following parameters.
Temperature 
Filter 
T0 
DT
Abnormal Absorbance 
Blank 
Test Mode 
Print Out 
Standard Value 
Number of Prints 
Test Code
Once this blank had been successfully loaded, the 
parameter 'blank' was changed to 'HOLD', and the blank 
disc cleared. 'DT' was then changed to 35 minutes, 'Print 
Out' to 'CONCENTRATION' and 'Standard Value' to '500'. 
These parameters were then loaded, the test disc placed in
:340 nm 
:5 seconds 
:15 seconds 
: 2. 0 U 
: AUTO 
: TERM
:Absorbance 
: 0000 
:1 
: 00
(82)
the CentrifiChem rotor, and the analysis performed.
The oxalate concentrations in the quality controls 
and the patients' samples were calculated by subtracting 
the calculated 'blank' concentrations from their 
respective 'test' concentrations on the CentrifiChem print 
out.
3.4. Linearity.
♦
Aqueous oxalate standards up to 1 mM and aqueous 
formate standards up to 3 mM were prepared and run as 
described in section 3.3. The results are shown in figures 
2.14. and 2.15. respectively. The method was shown to be
linear to at least 1 mM for aqueous oxalate and to 2 mM
for aqueous formate. The formate or 'blank' concentration 
of 11 urine samples was estimated, and found to range 
between 108 and 560 uM (mean= 310 uM + 153).
Overall the method was shown to be linear to a
urinary oxalate value of at least 1 mM. Even where 
elevated levels of endogenous urinary formate were 
present, the results remained within the linear range of 
the method. No urine specimens were found that exceeded 
this range.
(83)
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3.5. Precision. ~ •
3.5.1. Within run precision.
The within run precision was estimated on four
urine specimens. The results are shown in table 2.13.
The' coefficients of variation’ ranged from 3.47 to
7.61 %, and the mean values of the urine samples from 139
to 397 uM. This level of precision was comparable to the
%
precision found with the reference mathod.
3.5.2. Between run precision.
Three urine specimens were used to estimate the 
between run precision. All were acidified pooled 
specimens, aliquoted, lyophilised and stored at -20 
°C, reconstituted with distilled water prior to use.
The results are shown in table 2.14.
The coefficients of variation' ranged from 6.23 to 
9.47 %, and the mean values of the urine samples from 149
to 348 uM. This was an acceptable level of precision over 
a concentration range likely to be found in urine.
3.6. Recovery.
3.6.1. Recovery from urine.
Nine separate urine samples were 'spiked' with 300
(84)
Table 2.13. Within run precision of the enzymic procedure.
SAMPLE n MEAN(uM) S.D* C.V.%
1 6 139 10.6 7.61
2 6 204 9.97 4.88
3 6 357 9.86 6.76
4 6 397 13.8 3.47
Table 2.14. Between run precision of the enzymic procedure.
SAMPLE n MEAN (uM) S.DV C.V.%
1 22 149 14.1 9.47
2 12 210 18.6 8.86
3 13 348 21.7 6.23
uM oxalate. The recoveries obtained ranged from 92 to 107 
% (mean = 97.8 % + 5.57).
3.6.2. Samp1e dilution.
Three urine specimens were assayed undiluted and 
diluted 1 in 2 with distilled water. The results are shown 
in table 2.15.
The mean recovery from all three samples was 104 % 
( + 2.0).
3.7. Interferences.
The six potential interfering compounds ascorbate, 
glucose, glycine, serine, and tryptophan were investigated 
by addition to the assay medium for the enzymic assay. The 
mean recoveries and results of paired t-tests for 4 urines 
are shown in table 2.16.
No statistically significant interferences were 
found although tryptophan tended to produce slightly lower 
values for the urinary oxalate when compared to the 
'unspiked' sample. The mean recovery in all these 
experiments was found to be 98.6 % ( 7.30).
3.8. Correlation of the enzymic and colorimetric 
procedures.
Forty five urine samples were assayed by both the
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Table 2.15. Effect of sample dilution in the enzymic
procedure.
% '
SAMPLE NEAT (uM) DILUTED (uM) RECOVERY %
1 128 68 106
2 175 89 102
3 318 165 104
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reference method in section 1. and by the enzymic method 
described in this section. The results are displayed in 
figure 2.16. The correlation coefficient was found to be 
0.924.
A pair difference- t-test of the reference method - 
the enzymic method gave the following results: 
number of points :45
mean difference :-26.7
standard deviation :55.7
standard error : 8. 30'
students t value : -3.216
The value of the students t-test indicated that 
the enzymic method produced results which were 
significantly higher than the reference method at a 
probability level of P< 0.01.
3.9. Reference range. /
The urinary oxalate excretion of 20 healthy non 
fasting adults was found to range from 257 to 605 umol/vol 
(mean = 384 _+ 22.4 umol/vol) .
3.10. Discussion.
The enzymic assay described would seem to provide 
considerable advantages over methods reported earlier. The 
recent introduction of commercially available oxalate
(86)
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FIGURE 2.16. CORRELATION OF THE ENZYMIC AND THE REFERENCE 
OXALATE PROCEDURES'
decarboxylase and formate dehydrogenase ensured a constant 
supply of standardised enzyme preparations. The 
preparation of reagents was therefore simpler and quicker 
since no lengthy enzyme preparations were required.
No sample extraction before assay was required and 
since sample preparation was kept to a minimum it was 
possible to use small volumes of urine (less than 5 ml).
The linearity of the method has been shown to be 
adequate for all urine samples encountered. The between 
run precision of this assay was better than the precision 
of the reference method at comparable oxalate 
concentrations, and the within run precision was similar 
for both methods.
No significant interference was found from the six 
components investigated and the mean recovery of oxalate 
from urine was 97.8 % +_ 5.57.
The correlation between this method and the 
reference method described in section 1 was good (r = 
0.924). The generally higher results produced by the 
enzymic method would be expected due to the increased 
recovery of oxalate of 97.8 % compared to that of the
reference method of 75.4 %. The reference range was
accordingly higher when compared to the reference method.
The reagents used in this enzymic assay were 
considerably less hazardous than those required for the 
reference method, and the procedure was simple.
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4. URINARY ALLOPURINOL AND OXIPURINOL SCREEN BY HIGH
PERFORMANCE LIQUID CHROMATOGRAPHY.
The procedure for the determination of urinary 
allopurinol and oxipurinol described by Miyazaki et al 
(1983) was used.
4.1. Materials.
Unless otherwise stated, aj.1 materials were of 
AnalaR grade supplied by BDH, England.
20 mM disodium hydrogen orthophosphate
3.56 g Na2HP04.2H20 (m. wt. = 177.99)
dissolved in 1 litre of distilled water.
4_ mM disodium hydrogen orthophosphate
0.71 g Na2HP04.2H20 (m. wt. = 177.99)
dissolved in 1 litre of distilled water.
20 mM sodium dihydrogen orthophosphate
3.12 g NaH2P04.2H20 (m. wt. = 156.01)
dissolved in 1 litre of distilled water.
4_ mM sodium dihydrogen orthophosphate
0.62 g NaH2P04.2H20 (m. wt. = 156.01)
dissolved in 1 litre of distilled water.
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Diluent buffer _
20 mM phosphate buffer, pH 8.0
20 mM sodium dihydrogen orthophosphate added slowly to 20 
mM disodium hydrogen orthophosphate to reach pH 8.0.
Mobile phase
4 mM phosphate buffer, pH 6.0
4 mM disodium hydrogen orthophosphate added slowly to 4 mM 
sodium dihydrogen orthophosphate to reach pH 6,0.
Allopurinol / oxipurinol standard
27.2 mg allopurinol (Sigma Chemical Company) and 30.4 mg 
oxipurinol (Sigma Chemical Company) dissolved in 1 litre 
of distilled water.
HPLC column
25 cm x 4.6 mm stainless steel (Chrompack U.K.). "
Stationary phase
5 u ODS Hypersil (Shandon Southern Products Limited, 
U.K.).
Pump
Gilson model 302 (Gilson Medical Electronics, U.S.A.).
Pulse dampener / pressure indicator
Gilson model 802, Manometric Module (Gilson Medical 
Electronics, U.S.A.).
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Automatic sample injector
'WISP' model 710 B (Waters Associates, Cheshire, England). 
Detector
Altex model 160 variable wavelength UV detector (Beckman, 
U.K.) .
Recorder
Flat bed single pen recorder (Chessel'Limited).
HPLC fittings
All fittings were of the 'Swagelok* type and all 
connecting tubing was of 1/16 " stainless steel (Scotlab 
Instrument Sales Limited, Scotland).
4.2. Procedure.
The mobile phase was pumped at a flow rate of 1
ml/minute which produced a back pressure of 1000 - 1500
psi. The detector sensitivity was set to 0.02 absorbance 
units full scale at a wavelength of 254 nm, and the 
autosampler programmed to inject 25 ul of sample and to 
allow a run time of 50 minutes per sample. The chart 
recorder was run at 1 mm/minute.
200 ul of urine sample or standard was added to 2
ml of the diluent buffer in a sample vial: standards were
placed at intervals of 15 samples. Up to 48 samples and
(90)
standards could be processed in a single run.
The presence of allopurinol and oxipurinol was 
determined by comparing the retention times of the 
standard allopurinol and oxipurinol peaks with peaks 
observed in the sample chromatograms. The retention time 
of oxipurinol was 16.4 minutes and of allopurinol was 19.0 
minutes.
4.3. Discussion.
The method outlined above was used as a screening 
procedure to assess the presence of alloprinol and
oxipurinol in urine samples. Urines were considered to be 
positive if peaks were noted for either oxipurinol or 
allopurinol or both in the sample chromatogram.
The procedure was essentially the same as that 
described by Miyazzaki et al (1983) with the exception of 
the column packing material which, in the original 
reference was 10 u in diameter and employed in a guard 
column, but in this instance was 5 u in diameter and no 
guard column was used. This Imodification did not appear to 
make any difference to the chromatographic system.
Figure 2.17. represents the chromatograms of an 
aqueous standard, a blank urine and a standard urine 
respectively. The retention times of 16.4 and 19.0 minutes 
for oxipurinol and allopurinol were similar to the figures 
quoted by Miyazaki et al (1983) of 16.0 and 18.8 minutes.
The use of the autosampler enabled a full sample
(91)
Ox
ip
ur
in
ol
rack to be processed over a 40 hour period.
5. URINARY BENDROFLUAZIDE SCREEN BY THIN LAYER 
CHROMATOGRAPHY (TLC).
The procedure for the detection of thiazide 
diuretics described by Sohn et al (1973) was used after 
adaption of the column extraction procedure to the 'Prep 
I' (Du Pont Instruments) automated sample processor.
5.1. Materials.
Unless otherwise stated all materials were of 
AnalaR grade, supplied by BDH, England.
TLC Plates
Silica gel 60 ^254 precoated onto plastic sheets, 20 x 
20 cm. Layer thickness 0.2 mm (E. Merck, Darmstandt).
Ethyl acetate
99.0 % CH3COOC2H5 (m. wt. = 88.11).
Methanol
CH^OH (James Burrough, England).
Ammonia
35 % NH3, specific gravity.=0.88, (m. wt. = 17.03).
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Acetone
99.5 % (CH3)2.CO, (m. wt. = 58.08).
DMAB
Dimethylamino benzaldehyde (m. wt. = 149.19)
Extraction cartridges
'Type W f extraction cartridges, containing 90 mg cross 
linked styrenedivinylbenzene macroreticular resin, with 
activator (Du Pont Instruments). '
Developing solvent
Ethyl acetate : methanol : ammonia, 170 : 20 : 10l:iV:ViV. 
Revealing spray
Alkaline dimethylaminobenzaldehyde
2 g DMAB dissolved in 75 ml of 80 % acetone and 25 ml of 
ammonia. •
Standard bendrofluazide 
10 mg/litre bendrofluazide
One 5 mg bendrofluazide tablet (Berck) dissolved in 500 ml 
of distilled water.
5.2. Instrumentation.
Sample preparation was carried out using a Prep I 
automated sample processor (figure 2.18.).
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FIGURE 2.18. THE DU PONT 'PREP I' AUTOMATED SAMPLE PROCESSOR
This instrument was able to prepare liquid samples 
for analysis by extracting and, as a program option, 
concentrating components of interest. Up to 12 samples 
were able to be processed at one time to obtain either wet 
or dry extracts depending on the program selected.
Extraction was carried out under centrifugal force 
using a 12 position rotor attached to a bi - directional 
motor. Changes in rotor rotation rate and direction 
effected the required extraction and elution into the 
appropriate receivers. '
During clockwise rotation, the extraction columns 
aligned with a waste receiver, the samples driven through 
the columns by centrifugal force and the columns washed 
with solvent from the first solvent reservoir. In the 
reverse direction, the columns re - aligned with the 
sample recovery cups and the components were eluted with 
the solvent from the second solvent reservoir. The samples
were then dried down under a stream of warm air as the
rotor spun.
The extraction cartridge assembly consisted of a 
resin column with reservoir, an effluent cup and a sample 
recovery cup which were placed in their respective 
positions within the rotor assembly.
5.3. Procedure.
4 ml of the urine sample or standard was added to
the column reservoir and the extraction cartridge assembly
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was placed in the rotor. Program number 15 was selected 
and, at this stage, program step 1 was selected manually
and activated. After 3 minutes, the rotor was stopped and
a further 4 ml of the sample was added to the column 
reservoir. To the first solvent reservoir was added 50 ml 
of distilled water as the column wash solvent, and to the 
second solvent reservoir was added 50 ml of ethyl acetate
as the eluting solvent. Program number 15 was then reset 
and allowed to proceed automatically with the drying 
temperature set at 60 °C. Detai'ls of the program
steps are shown in table 2.17.
After completion of the extraction program, the 
dried residue was redisolved in 50 ul of acetone. 25 ul of 
this solution was then spotted onto a tic plate. A further 
50 ul of acetone was added to the sample cup and a further 
25 ul of this solution was loaded onto the same spot.
The tic plate was then placed in a developing tank
containing the developing solvent until the solvent front 
had progressed at least 10 cm from the origin after which 
the plate was removed and allowed to air dry.
The spots were revealed under a UV lamp at 254 nm 
and confirmation of the presence of thiazide was carried
out by spraying the plate with the revealing agent
alkaline DMAB to produce yellow spots.
5.4. Discussion.
A urine sample was considered to contain
(95)
Table 2.17. 1 Prep 11 extraction program.
%
STEP NUMBER STEP FUNCTION DURATION (Minutes)
1 Extract 3.00
2 Extract 1.00
3 Continue 0.30
4 Dispense solvent(wash) 0.30
5 Collect(waste) 2.00
6 Spin 1.00
7 Coast 0.30
8 Reverse 0.05
9 Reverse 0.10
10 Dispense solvent(elute) 0.30
11 Collect(sample) 2.00
12 Collect(sample) 1.00
13 Evaporate 18.00
14 Cool 0.15
bendrofluazide and therefore indicate compliance with 
therapy if under ultraviolet light a component was 
revealed in the sample which was at a similar Rf and of a 
similar blue colour as that of the standard which on 
subsequent spraying with DMAB produced a yellow colour.
The Rf of bendrofluazide was found to be 0.70 and 
all spots revealed under UV produced the yellow colour 
reaction when sprayed with DMAB.
Under UV, two other components noted in the
standard at an Rf of 0.82 and 0.43 respectively, which did 
not produce a yellow colour on spraying, were considered 
to be compounds used • . in the formulation of the 
bendrofluazide tablet used to prepare the standard.
6. ROUTINE LABORATORY ESTIMATIONS.
The following biochemical tests were performed
through the routine biochemistry services at the Glasgow
Royal Infirmary.
6.1. Estimations in blood.
Table 2.18. represents the methods of analysis 
used by the routine laboratory for the analysis of calcium 
(monthly CV = 1.4 % at 1.97 mmol / litre, n = 22),
magnesium (monthly CV = 2.5 % at 0.80 mmol / litre, n =
24), zinc (monthly CV =1.9 % at 19.12 umol / litre, n =
22) and urate (monthly CV = 2.2% at 198 umol / litre, n =
(96)
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18) in serum with the departmental reference ranges.
6.2. Estimations in urine.
Table 2.19. represents the methods of analysis 
used by the routine laboratory for the analysis of calcium 
(monthly CV = . 1.3 % at 3.43 mmol / litre, n = 21), 
magnesium (monthly CV = 2.4 % at 1.23 mmol / litre, n =  
24), creatinine (monthly CV =1.3 % at 0.93 mmol /litre, 
n = 22) and urate (monthly CV '= 1.8 % at 0.60 mmol / 
litre, n = 1 8 )  in urine with the departmental reference 
ranges.
(97)
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CHAPTER 3. CLINICAL STUDIES.
1. THE CLINICAL STUDY OF STONE FORMERS.
1.1. Protocol.
Patients presenting at the outpatient clinic of 
the Urology Department with a proven 'stone incident1 and 
with no previous active therapy for renal stones were 
considered for this study. A 'stone' incident' was defined 
as acute renal colic, spontaneous passage of a stone, 
radiological confirmation of a new stone or surgical 
removal of a new stone.
1.1.1. Initial patient work up.
Baseline investigations for each patient were as
follows:
previous stone disease history 
'age . '
' sex
biochemistry (table 3.1.)
bacteriology (mid stream specimen of urine ) 
radiology (intravenous urography)
1.1.2. Selection of treatment regime.
Patients, who on initial investigation, presented
(98)
Table 3.1. Biochemical investigations in stone formers.
Specimen Test
Blood Calcium concentration 
Magnesium concentration 
Zinc concentration 
Urate concentration
24 hour urine Calcium excretion 
Magnesium excretion 
Creatinine excretion 
Urate excretion 
Oxalate excretion j
with a 24 hour urinary calcium excretion of less than 8.0 
mmol /volume were randomly ascribed allopurinol, 300 mg /
day or bendrofluazide, 5 mg / day with potassium
supplement. These subjects were designated treatment
groups 1 and 2 respectively.
Patients, who presented with a urinary excretion 
of calcium of more than or equal to 8.0 mmol / vol were
ascribed bendrofluazide, 5 mg/day with potassium 
supplementation. These subjects were designated treatment 
group 3.
1.1.3. Clinical follow up.
Patients were requested to attend the outpatient 
clinic on a 3 monthly basis, at which times the
biochemical and bacteriological investigations were
repeated; at yearly intervals, where possible, a plain 
abdominal radiograph was undertaken, observing the 10 day 
rule for female subjects.
1.1.4. Compliance.
The compliance of each subject with their
respective therapy was monitored retrospectively by the 
procedures described in sections 2.4. and 2.5. For
inclusion in the final analyses the presence of the 
respective drug in at least 66 % of the urine samples
analysed for each subject was required.
(99)
1.2. Patients.
Eighty eight subjects were considered for the 
study. However, 8 male and 4 female subjects were excluded 
as shown in table 3.2. prior to any clinical follow up.
The previous medical histories and the presenting 
conditions of the 50 male and 26 female subjects that
remained are shown in tables 3.3. and'3 .4. repectively.
The mean age of all subjects was 49.4 _+ 12.0
years (n = 7 6 )  and there were no significant differences 
in the distribution of age between the three groups and 
sexes (unpaired t - test).
1.3. Results; Group 1.
1.3.1. Exclusions.
Thirty two subjects were assigned to this group.
However, 2 male and 2 female subjects were excluded due to 
non compliance with therapy. A further 5 male subjects
were excluded due to failure to attend or provide
specimens at the clinic. 24 subjects, 17 males and 7 
females remained in group 1.
The mean age was 51.6 + 11.7 years (n = 24) and 
there was no significant difference in the mean age
(100)
Table 3.2. Patients excluded prior to follow up.
Reason Male Female
Reaction to allopurinol 3 1
Reaction to bendrofluazide 0 1
Defaulted from therapy 2 1
Incomplete work up 2 0
Pregnancy 1
Relocation 1 0
Total 8 4
Table 3.3. Previous renal stone hi stories of all subjects.
History Male Female
Nil 27 ' 14
Renal colic 5 3
Renal stone 13 7
Operation
Ureterolithotomy 2 0
Nephrectomy 1 1
Pyelolithotomy 2 1
Total 50 26
Table 3.4, Presenting renal stone incident of all subjects
Condition Male Female
Renal colic 8 1
Renal stone 35 15
Operation
Ureterolithotomy 6 5
Nephrectomy 0 1
Pyelolithotomy 1 4
Total 50 26
between the sexes (unpaired t - test).
1.3.2. Clinical results.
The mean period of follow up for this group of
patients was 19.7 +_ 7.26 months (n - 24) which
represented a total of 39.4 patient years. During this 
time 4 male subjects (16.7 %), one of whom presented with 
a recurrent urinary tract infection,' suffered a total of 6 
stone incidents (table 3.5.) with a mean period to the 
first recurrence of 8.75 + 4.03 months (n = 4). A single 
female subject presented with a recurrent urinary tract 
infection.
1.3.3. Biochemical results.
The mean urinary excretion of oxalate, calcium,
urate and magnesium, pretreatment, after 3 months of
therapy and after 9 to 15 months of therapy are shown in 
figures 3.1. and 3.2.
The mean serum concentration of calcium,
magnesium, zinc and urate, for the same periods of
therapy, are shown in figures 3.3. and 3.4.
The Wilcoxon paired signed rank test of the
difference between two medians was applied to the
pretreatment and subsequent values of the analytes
mentioned above, and the following results were found:
(101)
Table 3.5. Stone incidents in group 1 subjects.
Males Females
7
0
0
Total 17 7
Incident free 13
Single incident 3
Multiple incidents 1
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a) There was a significant increase in the urinary 
calcium excretion after 3 months of therapy (p < 0.025 )
as shown in figure 3.1., the mean value rising from
4.93 _+ 1.73 to 6.12 + 2.83 mmol / volume (n = 22).
b) The serum zinc concentration was increased (p < 
0.025) after 9 to 15 months of therapy from a mean value
of 13.2 +_' 2.43 to 14.2 _+ 2.01 umol / litre (n = 11) .
c) The serum urate concentration was significantly 
reduced after 3 months and after 9 to 15 months of therapy
(p < 0.05 in both time intervals) as' shown in figure 3.4.,
the mean value falling from 322 + 76.1 to 275 +_ 102
umol / litre (n = 13) and from 335 _+ 91.8 to 255 +_
75.4 umol / litre (n = 15) respectively.
There were no significant changes noted in the
urinary oxalate and magnesium excretions nor in the serum 
calcium and magnesium concentrations.
1.4. Results: Group 2.
1.4.1. Exclusions.
Thirty one subjects were assigned to this group. 
However, 3 male and 3 female subjects were excluded due to 
non compliance with therapy. A further 1 male and 1 female 
subject were excluded due to failure to attend or to
provide specimens at the clinic .Finally, 23 subjects, 13 males a 
10 females remained in group 2.
(102)
The mean age was 46.0 + 13.3 years (n = 23) and
there was no significant difference in the mean age of the 
sexes (unpaired t - test).
1.4.2. Clinical results.
The mean period of follow up for this group was
23.2 _+ 6.59 months (n = 23) which represented a total of
44.5 patient years. During this time 3 male and 2 female 
subjects (21.7 %) suffered a total' of 18 stone incidents
(table 3.6.) with a mean period to the first recurrence of 
9.40 +_ 5.18 months (n • = 5). One other female subject
presented with a recurrent urinary tract infection.
1.4.3. Biochemical results.
* The mean urinary excretion of oxalate, calcium,
urate and magnesium, pretreatment, after 3 months of 
therapy and after 9 to 15 months of therapy are shown in 
figures 3.5. and 3.6.
The mean serum concentrations of calcium, 
magnesium, zinc and urate, for the same periods of
therapy, are shown in figures 3.7. and 3.8.
When the Wilcoxon paired signed rank test was
applied the following results were found:
a) There was a significant decrease in the serum
magnesium concentration after 3 months and after 9 to 15
(103)
Table 3.6. Stone incidents in group 2_ subjects.
Males Females
Incident free 10 8
Single incident 2 1
Multiple incidents 1 1
Total 13 10
Ur
in
ar
y 
ox
al
at
e 
(u
mo
l/
vo
l)
 
Ur
in
ar
y 
ca
lc
iu
m 
(m
mo
l/
vo
l)
A
10
•4 . -
0
A
600
400
200
0
Time on therapy 
(months)
A
10 -
O
A
600 «
400
200 -
0
9-15
1
9-15
Time on therapy 
(months)
FIGURE 3.5. URINARY CALCIUM AND OXALATE EXCRETION DURING
BENDROFLUAZIDE THERAPY (GR0UP2)
Ur
in
ar
y 
ma
gn
es
iu
m 
(m
mo
l/
vo
l)
 
Ur
in
ar
y 
ur
at
e 
(m
mo
l/
vo
l)
A A
O
O
0
O 9-15
A
8 -
2 -
0 l— -------- r
O .3
Time on therapy 
(months)
A
6 -
O
* Significant 
p < 0.05
T"
0 3
Time on therapy 
(months)
FIGURE 3.6. URINARY URATE AND MAGNESIUM EXCRETION DURING
BENDROFLUAZIDE THERAPY (GROUP 2)
Se
ru
m 
ma
gn
es
iu
m 
(m
mo
l/
1)
 
. 
Se
ru
m 
ca
lc
iu
m 
(m
mo
l/
1)
A
2 -
O
T
n L r i n
2
1
O
9-15O
1.0 A
0.5
0
* Significant 
p < 0.05
T
O 3
Time on therapy 
‘(months) .
1.0
A
0.5
0
* Significant
p < 0.01
I
T
O 9-15
Time on therapy 
(months)
FIGURE 3.7. SERUM CALCIUM AND MAGNESIUM CONCENTRATIONS DURING
BENDROFLUAZIDE THERAPY (GROUP 2)
Se
ru
m.
ur
at
e 
(u
mo
l/
1)
 
Se
ru
m 
zi
nc
 
(u
mo
l/
1)
A A
20 20 -
16 — 16 _
12
8 -
4 - 4 -
0
A
600 -
400
200
1 ----  J
0 3
_ Time on therapy 
(months)
0-
A
600
400
200
~ r
9-15
* Significant
p < 0.01
~t----- — r
0 9-15
Time on therapy 
(months)
FIGURE 3.8. SERUM ZINC AND URATE CONCENTRATIONS DURING
BENDROFLUAZIDE THERAPY (GROUP 2)
months of therapy (p <0.05 and p <0*01 respectively) as 
shown in figure 3.7., the mean values falling from 0.76 
0.066 to 0.72 +_ 0. 046 mmol / litre (n = 7) and from
0.78 + 0 . 0 7 7  to 0.71 + 0.051 mmol / litre (n = 9).
b) There was an increase in the urinary magnesium 
excretion after 9 to 15 months of therapy (p < 0.05) as
shown in figure 3.6. the mean value rising from 2.94 _+
1.08 to 3.78 + 1.41 mmol / volume (n =17).
c) The serum urate concentration rose
significantly (p < 0.01) after 9 to' 15 months of therapy,
as shown in figure 3.8. from a mean value of 307 _+ 96.2
to 370 + 95.6 umol / litre (n = 12).
There were no significant changes noted in the 
urinary calcium, oxalate, and urate excretions nor in the 
serum calcium and zinc concentrations.
1.5. Results: Group 3 .
1.5.1. Exclusions.
'^0   —  .
Thirteen subjects were assigned to this group. 
However, 5 male and 1 female subjects were excluded due to 
non compliance with therapy. ^inally^  7 subjects, 6 male and 1 
female remained in group 3.
The mean age was 42.9 _+ 9.8 years (n = 7) and
there was no significant difference in the mean age 
between the sexes (unpaired t - test).
(104)
1.5.2. Clinical results.
The mean period of follow up for this group of
patients was 20.3 +_ 6.45 months (n = 7) which
represented a total of 11.8 patient years. During this 
time 1 male subject (14.3 %), who also presented with a 
recurrent urinary tract infection, suffered a single stone 
incident after 14 months of therapy'. The single female in 
this group also presented with a recurrent urinary tract
infection.
1.5.3. Biochemical results.
The mean urinary excretion of oxalate, calcium,
urate and magnesium, pretreatment, after 3 months of 
therapy and after 9 to 15 months of therapy are shown in 
figures 3.9. and 3.10.
The mean serum concentrations of calcium, 
magnesium, zinc and urate, for the same periods of
therapy, are shown in figures 3.11. and 3.12.
When the Wilcoxon paired signed rank test was
applied, the following results were found:
a) There was a significant fall in the urinary
calcium excretion after 3 months of therapy (p < 0.05) 
- : j from a mean value of 10.8 +
(105)
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FIGURE 3.12. SERUM ZINC AND URATE CONCENTRATIONS DURING
BENDROFLUAZIDE THERAPY (GROUP 3)
3.39 to 7.10 + 3.23 mmol / volume (n = 6) as shown in
figure 3.9.
b) There was a significant rise in the urinary
oxalate excretion (p <0.025) after 3 months of therapy, 
as shown in figure 3.9. from a mean value of 300 +_ 95.2
to 354 +_ 69.2 umol / volume (n = 6).
c) There was a significant increase in the serum 
urate concentration after 9 to 15 months of therapy (p < 
0.05), as shown in figure 3.12., from a mean value of ‘354 
+ 62.7 to 430 +/. 68.9 umol / litre '(n = 5).
There were no significant changes noted in urinary 
magnesium and urate excretion nor in serum calcium,
magnesium and zinc concentrations.
When an unpaired t - test was applied to the mean 
values for each analyte mentioned above, from each of the 
3 groups, the following results were found:
a) The mean urinary excretion of calcium for group
3 subjects of 9.91 _+ 3.96 mmol / volume (n = 7) was
significantly greater (unpaired t - test) than the mean 
values for group 1 subjects of 4.97 +_ 1.66 mmol / volume
(n = 24) and for group 2 subjects of 4.84 + 2 . 0 2  mmol /
volume (n = 22, p < 0.001 in both cases). A significant
difference was observed between the values, after 3 months 
of therapy, for group 3 subjects of 7.19 +_ 3.29 mmol /
volume (n = 6) and for group 2 subjects of 4.47 +_ 2.09
mmol / volume (n = 18, p < 0.05) but not between groups 3 
and 1, and no significant differences were noted after 9 
to 15 months of therapy.
(106)
b) The mean pretreatment urinary excretion of
urate for group 3 subjects of 5.04 +_ 1.84 mmol / volume 
(n = 7) was significantly greater than the mean value for 
group 1 subjects of 3.40 1.03 mmol / volume (n = 22, p
< 0.05). A significant difference was observed between the
values after 3 months of therapy for group 3 subjects of 
3.98 .+ 0.96 mmol / volume (n = 6) and for group 1
subjects of 2.86 + 0.81 mmol / volume (n = 22, p <
0.01), and after 9 to 15 months of therapy between the 
group 3 mean value of 4.54 +_ 2.17’ mmol / volume (n = 7) 
and the group 1 mean value of 3.07 + 1.29 mmol /volume 
(n = 20, p < 0.05).
1.6. Discussion.
The overall ratio of male to female patients 
considered for this study was 1.93 to 1.0 which was in
general agreement with other studies, in which the 
incidence of symptomatic stone disease in males was 
considered to be greater than in females (Hodgkinson 1977, 
Robertson et al 1980a).
The overall compliance to therapy of the subjects 
ascribed allopurinol was 87.5 % which was an acceptable
level for a closely followed group taking a single daily 
dose. The overall compliance of the subjects ascribed 
bendrofluazide was slightly less, being 72.7 %, possibly 
due to the necessity of concurrent therapy with potassium
(107)
supplements which were required to be taken 3 time per 
day, and which may, on occassion, produce gastric upset 
(Data Sheet Compendium 1978a).
Adverse reactions attributed to bendrofluazide and 
necessitating withdrawal of therapy were rare and occurred 
in only 1 female subject representing 2 % of all subjects 
ascribed to the drug. Adverse reactions attributed to 
allopurinol. were more common and occurred in 3 male and 1 
female subject, representing 13 % of all subjects ascribed 
such therapy. Bendrofluazide has been recognised as having 
a low incidence of side effects (Data Sheet Compendium 
1978b), and a similar incidence of reactions to 
allopurinol therapy of 9.8 % has been reported (Scott,
Mathieson and McLelland 1979).
When the presenting renal stone incidents of all 
female subjects were considered, 38.5 % presented having 
required surgical intervention compared to 14.0 % of all 
males. This implied that clinical stone disease, although 
rarer in females, was of a more severe nature than that 
observed in males, although no reason for this was 
apparent.
The incidence of urinary tract infection found 
during the present study was 7.7 % in females and 4.0 % 
in males.
The presence of a urinary tract infection did not 
relate to the requirement for initial surgical 
intervention, and the infection rates were not 
sufficiently different to account for the apparent
(108)
difference in the severity of symptomatic stone disease 
observed between the sexes.
Figure 3.13. represents the percentage of subjects 
stone-free versus time, after an initial stone incident, 
which was found in an untreated group of subjects (Coe 
1980). Also plotted in this figure are the percentages of 
subjects that were stone - free, at the end of the study, 
versus the mean time of follow up for each group. For each 
group, the recurrence of stone was less than was shown for 
the untreated group but, although this may have been the 
case and although it may be more pronounced after an 
increased period of follow up, only a general comparison 
between the treated and untreated groups may be made in 
this instance.
Allopurinol therapy has been shown to reduce the 
recurrence of stone disease in hyperuricaemic or 
hyperuricosuric stone formers alone (Coe and Raisen 1973, 
Smith 1977, Coe 1977) and in metabolically normal stone 
formers in conjunction with thiazide diuretics (Coe 1977).
The rationale behind the allopurinol regime was 
that, as a xanthine oxidase inhibitor, allopurinol would 
reduce the oxidation of xanthine and hypoxanthine to uric 
acid and may also reduce the urinary excretion of oxalate 
(Scott et al 1978a, Scott et al 1978b).
It has been suggested that uric acid or sodium 
urate crystals could promote calcium stone formation by 
providing a substrate for the growth of calcium oxalate 
crystals; ie. epitaxy (Lonsdale 1968), therefore a
(109)
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reduction in urinary uric acid would reduce the 
probability of forming stones.
More recently, Robertson et al (1976) suggested 
that urinary urate might interfere with crystallisation 
inhibitors (glycosaminoglycans) in urine. A decreased
concentration of urate would therefore favourably affect 
the inhibition of calcium oxalate crystallisation. An
increase in the inhibition of crystal growth jin vitro 
during treatment with allopurinol has been shown (Tiselius
1980) but more recently Hallson, Rose and Sulaiman (1982) 
have shown that, in whole human urine, an increase in the 
urinary urate did not increase the calcium oxalate
crystals formed and these workers did not support the
suggestion that reducing urinary urate concentration may
be of value in the treatment of patients with stone 
disease
Urinary oxalate has been considered to be the 
major risk factor involved in renal stone formation 
(Robertson et al 1981) and the reduction of urinary 
oxalate excretion during allopurinol therapy has been 
shown by some (Scott et al 1978a, Scott et al 1978b) but 
not other workers (Tiselius 1980, Tiselius and Larsson
1982) .
Urinary calcium has been shown to be unchanged 
during allopurinol therapy (Scott et al 1978a, Scott et al 
1978b, Tiselius 1980, Tiselius and Larsson 1982) but in 
this study there was a significant increase in the urinary 
excretion of calcium after 3 months of therapy (P <
(110)
0.025), the mean value rising outwith the reference range, 
although this increase was not maintained after 9 to 15 
months of therapy.
The renal handling of calcium has been shown to 
involve almost complete reabsorption of filtered calcium? 
50 to 55 % reabsorbed in the proximal tubule, 20 to 30 % 
in the loop of Henle and 12 to 23 % in the distal tubule 
(Goldberg, Agus and Goldfarb 1976).
As some 50 % of calcium is reabsorbed in' the
proximal tubule any changes effecting urate, which is also 
handled predominantly in the proximal tubule might be 
expected to influence the final excretion Of calcium.
Alternatively, a number of varied adverse
reactions attributed to allopurinol (Data Sheet Compendium 
1983a) may be humoral in origin, and such effects may also 
influence the renal handling of calcium.
The finding that the calcium excretion was not
significantly different from the baseline value after 9 to 
15 months of therapy may indicate a chronic change in the
calcium balance of the subjects being studied.
The effect of seasonal changes in dietary calcium 
intake was unlikely to have been responsible for the 
observed data as allopurinol therapy was initiated in
different subjects at different times of the year.
Serum zinc levels, although shown to have
increased after 9 to 15 months of therapy (p < 0.05) are 
subject to large diurnal variations and should be
estimated on fasting blood samples. Although all blood
(111)
samples in this study were taken between 11.00 amd and mid 
-■ day, fasting samples were not specified and combined 
with the' low significance of this finding makes the
interpretation of this change, if any, difficult, although 
a chronic change in the serum zinc levels similar to that 
of the renal handling of calcium may have occurred. 
Urinary zinc excretion was not measured in this study due 
to the problem of sample contamination.
In this study group randomly ascribed allopurinol 
therapy there was a significant fall in the blood urate 
concentration after 3 months and after 9 to 15 months of 
therapy (p < 0.05 in both cases) due to the inhibitory
effect of allopurinol on xanthine oxidase, with the mean 
value remainig within the reference range. Although there 
was no significant change in the urinary excretion of
urate in this group, which was a similar finding from 
previous work in this department (Scott et al 1978) a 
significant fall during therapy has been observed ! by other 
workers' (Tiselius 1980, Tiselius and Larsson 1982).
The renal handling of urate in the rat has been
shown to involve complete glomerular filtration and
bidirectional transport limited to the proximal nephron. 
Reabsorption was almost complete during tubular passage 
therefore excreted urate was almost entirely derived from 
tubular secretion. (Lang et al 1979).
Although no significant decrease of urinary urate 
excretion was shown in this group a reduced serum urate 
concentration migh be expected to produce a fall in the
(112)
urinary urate excretion due to reduced tubular secretion.
Urinary oxalate excretion has been shown to be 
reduced in stone formers (Scott et al 1978) and in normal
male subjects receiving a high purine diet (Simmonds et al
1981) during allopurinol therapy, but no significant
difference in oxalate excretion was shown in this study 
which was in agreement with other studies (Tiselius 1980, 
Tiselius and Larsson 1982).
The role of xanthine oxidase in the endogenous
synthesis of oxalate has been shown 'to be small (Gibbs and 
Watts 1966) so the inhibition of this enzyme by
allopurinol was unlikely to have had a significant effect 
on oxalate excretion.
The renal handling of oxalate in the rat has been 
shown to be similar to that of urate in that it involved 
virtually complete glomerular filtration with tubular 
reabsorption and tubular secretion located in the proximal 
nephron (Lang et al 1981). Tubular secretion was shown to 
be inhibited by urate (Greger et al 1978); this implied
that the effect of allopurinol therapy, if any, would be
to increase rather than to decrease urinary oxalate 
excretion.
The lack of any significant change in urinary
oxalate excretion during allopurinol therapy may therefore 
be caused by a combination of reduced endogenous synthesis 
due to xanthine oxidase inhibition and an increased renal 
clearance due to the reduced inhibition of tubular 
secretion of oxalate by urate.
(113)
Bendrofluazide therapy has been successfully used 
to treat stone disease when given continuously (Backman et 
al 1979, Ljunghall 1981a), intermittantly (Rundle and 
Scott 1980) or in combination with magnesium oxide 
(Ahlstrand and Tiselius 1983). Other thiazide diuretics 
such as hydrochlorothiazide (Klein and Griffith 1981, 
Scholz, Schwille and Sigel 1981, Cohanim and Yendt 1981, 
Maschio et al 1981), trichlormethiazide (Coe 1977) and 
chlorthiazide (Klein and Griffith 1981) have also been 
shown to be of benefit in the prevention of the recurrence 
of kidney stone disease. However, in a report of a double 
blind controlled clinical trial of bendrofluazide versus a 
placebo, Brocks, Dahl and Wolf (1981) showed that although 
the thiazide group demonstrated a similar reduction in 
stone recurrence to that found by other workers, the 
placebo group had a reduction of the same magnitude, over 
a mean period of follow up of 1.6 years. In conclusion, 
Brocks et al (1981) concede that the period of follow up 
during therapy was short and a statement as to the long 
term benefits of thiazide therapy to these patients cannot 
be made.
Urinary calcium has been considered to be a 
significant risk factor involved in renal stone formation 
(Robertson et al 1981) and urinary magnesium has been 
shown to reduce calcium oxalate crystal formation in human 
urine (Hallson, Rose and Sulaiman 1982).
In the current study, 2 groups of patients were 
ascribed bendrofluazide with potassium supplements; a
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normocalciuric and a hypercalciuric group. In both groups, 
the serum urate concentration was shown to have risen 
significantly after 9 to 15 months of therapy, although 
the mean levels remained within the reference range, and 
there were no significant differences in the urinary 
excretion of urate during therapy.
Increased serum urate is a documented side effect 
of bendrofluazide therapy (Data Sheet Compendium 1978a) 
and has been reported by a number of workers during 
prolonged therapy (Jorgensen and Bfunner 1974, Backman et 
al 1979, Ljunghall et al 1981b) and in this instance was 
probably caused by the inhibition of tubular secretion of 
urate by competition at the tubular transport step from 
the diuretic agent (Lang et al 1979) .
Changes in the serum magnesium concentration with 
and without changes in the urinary magnesium excretion 
during bendrofluazide therapy have been demonstrated 
(Jorgensen and Brunner 1974, Backman et al 1979, Ljunghall 
et al 1981b)
In the present study, during bendrofluazide 
therapy, the normocalciuric subjects demonstrated a 
significant fall in the serum magnesium concentration 
after 3 months and after 9 to 15 months of therapy, and a 
significant increase in the urinary excretion of magnesium 
after 9 to 15 months of therapy. This represented a 
chronic renal loss of magnesium during therapy, probably 
caused by an effect of the bendrofluazide at the proximal 
end of the distal convoluted tubule, decreasing magnesium
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reabsorption.
Although no statistically significant changes on 
the serum concentration nor the urinary excretion of 
magnesium were seen in the hypercalciuric subjects during 
the present study, this was probably due to the limited 
size of the group.
The reduction of urinary calcium during 
bendrofluazide therapy has been shown in normocalciuric 
and in hypercalciuric subjects (Jorgensen and Brunner 
1974, Backman et al 1979, Ljunghall 'et al 1981b). A number 
of mechanisms accounting for this fall have been suggested 
including a decreased intestinal absorption of calcium 
(Yendt and Cohanim 1978), humoral effects particulary due 
to parathyroid hormone (Brickman, Massry and Coburn 1972) 
and a direct renal effect (Costanzo and Weiner 1974).
From the current data, only the hypercalciuric 
subjects showed a statistically significant fall in 
urinary calcium, after 3 months of therapy to a mean value 
which was still outwith the reference range. However, no 
significant difference was observed after 9 to 15 months 
of therapy probably due to the limited number of subjects 
within the group.
As the serum calcium concentration in this study 
was not significantly changed, the calcium balance of the 
subjects may have been changed, although the mechanism by 
which this was reached was unclear.
Yendt and Cohanim (1978) have shown a significant 
reduction in urinary oxalate excretion during chronic
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hydrochlorothiazide administration after at least 1 year
of therapy,and it has bean suggested that this was due to a
decreased intestinal absorption of calcium caused by
chronic hydrochlorothiazide therapy (Yendt, Gagne and
Cohanim 1965).
In the present study, a significant increase in 
the urinary oxalate excretion after 3 months of
bendrofluazide therapy was observed in the hypercalciuric 
subjects. Although this was contradictory to the
observations of Yendt and Cohanirft (1978), it has been
shown that there was a reduction in the renal excretion of 
oxalate during volume expansion ( Greger et al 1978) .
During thiazide therapy a degree of volume contraction 
might be expected and this in turn could produce an 
increased renal excretion of oxalate and therefore an 
increased urinary excretion.
The hypercalciuric group in the current study was 
selected only on the basis of an elevated urinary calcium 
excretion, and as such the mean pretreatment value of 
urinary calcium was significantly higher in this group 
than in the other two.
After 3 months of therapy, due to the 
hypocalciuric effect of bendrofluazide, there was no 
significant difference between the mean calcium excretion 
of the initially hypercalciuric group and the allopurinol 
group. However, there was still a significant difference 
between the two bendrofluazide groups, due to the limited 
reduction in urinary calcium excretion in the
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normocalciuric group.
As well as an elevated urinary calcium, there was 
a significantly higher urinary urate excretion, the mean 
value being outwith the reference range, in the 
hypercalciuric subjects when compared to the other two 
normocalciuric groups. Although this difference was 
resolved between the bendrofluazide groups during therapy, 
the mean urinary excretion of urate remained significantly 
higher in the initially hypercalciuric group than in the 
group randomly ascribed allopurinol. This was due to the 
reduced excretion of urate in the group receiving 
allopurinol.
2. INVESTIGATION OF URINARY OXALATE VARIATION IN NORMAL 
SUBJECTS USING THE ENZYMIC METHOD OF OXALATE ESTIMATION.
The importance of urinary oxalate excretion in 
stone disease has already been stated in chapter 1. and
the possible existence of a diurnal variation in the
urinary excretion or urinary concentration of oxalate has
been suggested by some (Hodgkinson 1970, Tiselius and
Almgard 1977, Bach et al 1979, Vahlensieck, Bach and Hesse
1982)but not all workers (Tocco et al 1979).
It has been suggested that such a diurnal rhythm
might lead to situations in which the 'risk' of stone
formation may be increased at a specific time of day
(Tiselius and Almgard 1977).
In this study the variation of oxalate excretion,
(118)
oxalate concentration and urine flow rate was examined in 
healthy volunteers diurnally and on a daily basis over 3 
consecutive days.
The subjects involved were also being followed to 
asses the pharmacokinetics of a single dose of the
antibiotic 'Tinidazole’. This drug was not known to have 
any effect on the excretion of oxalate (Data Sheet
Compendium 1983b).
2.1. Subjects and Methods.
5 male and 3 female laboratory staff aged between
19 and 40 years with no known pathological condition were
recruited to the study.
Subjects were requested to remain fasted from 
10.00 pm the previous evening and urine collection was 
commenced at 9.00 am on 1 day I 1 and continued as shown in 
table 3.7. until the end of 1 day 3'.
The subjects remained fasted until 13.00 h on ’day. 
1 ’ after which there were no dietary restrictions. During
the fasting period, free access to drinking water was
permitted to ensure an adequate urine output.
After sample collection, the volume of urine
passed was noted and an aliquot of the well mixed sample 
was acidified by the addition of concentrated HC1 to a pH 
of less than 3, and stored at -20 °C until analysis.
The oxalate estimation was performed using the
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Table 3.7. Sample collection periods.
Sample Collection Period
1. 09.00 - 11.00 h
2. 11.00 - 13.00 h
3. 13.00 - 15.00 h
Day 1 4. 15.00 - 17.00 h
5. 17.00 - 19.00 h
6. 19.00 - 21.00 h
7. 21.00 - 09.00 h
Day 2 09.00 - 09.00 h ;
Day 3 09.00 - 09.00
enzymatic procedure described and evaluated in chapter 2.
2.2. Results.
2.2.1. Specificity of the Enzymatic Assay.
A 2 mM aqueous solution of the antibiotic 
'Tinidazole' when estimated as per the assay procedure did 
not differ from the ’zero standard' value.
2.2.2. Exclusion of Subjects.
Of the 8 subjects recruited to the study 1 male 
and 1 female subject were excluded due to incomplete 
sample collection. The age range of the remaining 6 
subjects was 22 to 40 years.
2.2.3. Urinary Oxalate Excretion.
The diurnal variation of urinary oxalate excretion 
rate for the 6 subjects is shown in figure 3.14. The rate
of excretion varied throughout the 24 hour period and was
highest between 5.00 pm and 7.00 pm and generally lowest
‘ - ' !
during the night through to mid morning (9.00 pm toil.00am).
. - When a paired t-test was applied to the data no
statistically significant difference between any of the
time periods was shown. The mean excretion rate over the 
24 hour period was 13.8 uM/h ( + 2.32).
(120)
 r
oro
*QU)
+
cfO<uS QW
A
O
CM
O
f— l
oo
•
Ch
O
O
O
•
T"o
oo•
in
O
Oo. .
m
O
O
O
•
r—1
o
oo
.
* cn
CM
O w
O Vi
• 3
r—1 O
CM .C>w»
O
O. ra
cr> *o
H
o 0o. 0)
b
rH •H
E*
oo
in
r-i
o
O
CO
1—I
oom •
r—1
H
o. o.«
<y\
O
(anon/iouin) sqea uopsaoxs a^eiexo
FI
GU
RE
 
3.
14
. 
DI
UR
NA
L 
VA
RI
AT
IO
N 
OF 
UR
IN
AR
Y 
OX
AL
AT
E 
EX
CR
ET
IO
N 
RA
TE
The variation of the daily oxalate excretion rate 
over 3 consecutive days is shown in figure 3.15. No 
statistically significant differences, using a paired 
t-test was shown between the days. The mean excretion rate 
over the 3 day period was 12.9 umol/h ( -f 4.59).
The interindividual variation of the daily oxalate 
excretion over the 3 day study period shown in table 3.8. 
ranged from 6.5 to 64.7 % and the intraindividual
variation shown in table 3.9. ranged from 17.0 to 33.9 %.
2.2.4. Urinary Oxalate Concentration.
The diurnal variation of urinary oxalate 
concentration is shown in figure 3.16. No statistically 
significant difference was found between any of the time 
periods using a paired t-test. However, the general 
impression obtained from the histogram was of a lower 
oxalate concentration in the morning through to the mid 
afternoon (9.00 am to 3.00 pm) and a higher concentration 
from the mid afternoon and throughout the night (3.00 pm 
to 9.00 am). The mean oxalate concentration over the whole 
day was 245 urnol/l ( + 66.0).
The variation of the daily oxalate concentration 
over the 3 day study period is shown in figure 3.17. No 
statistically significant difference was found (paired 
t-test) and the mean oxalate concentration for all 6 
subjects was 244 umol/1 ( + 91.5).
The coefficient of interindividual variation of the daily urinary
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oxalate concentration over the 3 day study period shown in
table 3.10.CV ranged from 4.8 to 68.6 % and the 
CV 7
intraindividual jr variation shown in table 3.11. ranged from
27.0 to 45.4 %.
2.2.5. Urine Flow Rate.
The diurnal variation of urinary flow rate is 
shown in figure 3.18. There was a tendancy for urine flow 
rate to be reduced during the evening and night (7.00 pm 
to 9.00 am) and increased during the rest of the day. A 
paired t-test showed a significant fall in the urine flow 
rate between the 7.00 pm to 9.00 pm sample period and the
9.00 pm to 9.00 am sample period at the 5 % probability
level. The mean urine flow rate over the 24 hour period 
was 58 . 5 ml/hour ( +_ 11. 5) .
The variation of the daily urine flow rate over
the 3 day period is shown in figure 3.19. Using the paired
t-test, no statistically significant differences were
noted between the days and the mean daily urine flow rate
was 54.8 ml/hour ( ■+_. 13.3) .
: cv .
The interindividualvariation of the daily urine 
flow rate over the 3 day period shown in table 3.12.
ranged from 2.3 to 27.0 % and the intraindividual
CV variation, shown in table 3.13. ranged from 19.7 to 24.9
(122)
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2.2.6. Correlation of Results.
Linear regression analysis showed that there was a 
very highly significant correlation between the diurnal 
variation of oxalate concentration and the diurnal 
variation of oxalate excretion as shown in figure 3.20. A 
correlation coefficient of 0.6950 was found (n=42,
p<0.001).
A similar correlation was found between the mean 
daily oxalate concentration and the mean daily oxalate
excretion rate over the 3 day study period as shown in
figure 3.21. A correlation coefficient of 0.7869 was found 
(n=18, p<0.001).
A highly significant negative correlation was 
found between the diurnal urine flow and the diurnal 
oxalate concentration as shown in figure 3.22. A 
correlation coefficient of -0.4653 was found (n=42,
p<0.01).
2.3. Discussion.
With the development of the enzymatic procedure 
for urinary oxalate estimation described in chapter 2.3. 
oxalate determinations in a large series of samples was 
possible.
No statistically significant diurnal variation of 
urinary oxalate excretion or urinary oxalate 
concentration was found due to the wide range of values
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from individuals for each time period as shown by the 
large error bars, representing 1 standard deviation, in 
figures 3.14 and 3.16. However, general diurnal trends in 
oxalate excretion, concentration and urine flow rate were 
evident in figures 3.14, 3.16 and 3.18.
As subjects were fasted from 10.00 pm the previous 
evening until 1.00 pm on the day of the study, the 
generally low mean oxalate excretion rate observed between
9.00 am and 1.00 pm may represent the basal endogenous 
excretion of oxalate. The mean excre'tion rate subsequently 
increased until 7.00 pm and this may be associated with 
the dietary intake and absorption of oxalate and oxalate 
precursors. Although the sampling periods were too long 
during the night and early morning to provide detailed 
results, the fall in oxalate excretion rate over this 
period may be related to reduced dietary intake and 
absorption.
Increased urinary oxalate excretion associated 
with dietary intake has been shown in non stone forming 
subjects, as in this instance, and in stone forming 
subjects (Tiselius and Almgard 1977, Hargreave et al 1977, 
Vahlensieck, Bach and Hesse 1982).
Urinary oxalate concentration tended to be lower 
between 09.00 - 15.00 h and higher between 15.00 —  09.00 h 
(figure 3.16.) although no statistically significant 
differences were shown. Conversely, urine flow rate tended 
to be lower between 21.00 - 09.00 h and higher between
09.00 - 21.00 h (figure 3.18.). The fall in urine flow
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rate between the 7.00 pm to 9.00 pm and the 9.00 pm to
9.00 am" time periods was significant at the 5 %
probability level.
A highly significant negative correlation 
(p<0.001) was found between these two components (figure 
3.22.) which was similar to the relationship found by 
Tiselius and Almgard (1977). This indicated that at 
periods of low urine flow rate, the urinary oxalate 
concentration tended to be higher.
A very highly significant positive correlation was 
observed between the diurnal oxalate concentration and the 
diurnal oxalate excretion rate (n=42, r=0.6950, p<0.001) 
as shown in figure 3.20., and between the mean daily 
oxalate concentration and the mean daily oxalate excretion 
rate (n=18, r=0.7869, p<0.001) as shown in figure 3.21.
Although the urinary concentration of oxalate was
related to the urinary flow rate, these results confirmed 
the concept of Hargreave et al (1977) in which the
variation of oxalate excretion was not related directly to 
the rate of urine flow as had been suggested by others 
(Tiselius and Almgard 1977, Vahlensieck et al 1982) and 
that the urinary oxalate excretion was influenced more by 
other factors such as dietary intake and absorption. 
However, outwith these influences, an increase in the 
total oxalate excretion related to an increase in the 
urine flow has been shown by Zarembski and Hodgkinson 
(1969).
Over the 3 day study period there was no
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significant difference between the mean daily excretion 
rate of 'oxalate (figure 3.15.), the mean daily oxalate 
concentration (figure 3.17.) or the mean daily urine flow 
rate (figure 3.19.).
For all 6 subjects, the mean interindividual 
variations of the mean daily urinary oxalate excretion 
rate, the mean daily oxalate concentration and the mean 
daily urine flow rate were 28.8 % +_ 25.8 umol/h 28.1 %
23.1 j umol/1 and 15.9 % ■ ■ _+ 10.1 ml/h, and the mean
intraindividual variations were 30.8 % 12.5 umol/h, 36.3 %
_+ 9.2umol/i and 23.2 % +_ 3.0 ml/h respectively.
In all 3 instances, ’ the value for the 
interindividual variation was lower than the corresponding 
value for the intraindividual variation, although the 
difference was not statistically significant.
These values, in aggreement with those stated by 
Tocco et al (1979), emphasised the wide variations both 
within and between subject that were encountered which 
subsequently made the clinical interpretation and 
significance of the results possible in only general 
terms.
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CHAPTER 4. CONCLUSIONS.
1. The analysis of urinary oxalate.
The clinical interest in urinary oxalate is 
increasing, with a number of oxalate kits, based on 
enzymes, becoming available, and a wide variety of 
analytical techniques have been applied to the analysis of 
oxalate.
The analytical procedure 'developed during the 
current work has been shown to be precise accurate and, 
compared to the reference procedure, safe and easy to 
perform.
Had there been time, further development of the 
procedure might have led to suitable method for the 
routine estimation of both serum and urinary oxalate.
The interpretation of urinary oxalate analyses has 
been shown to be complicated by the large inter and 
intraindividual variation of oxalate excretion in normal 
subjects and the possibility of a diurnal variation of 
oxalate excretion has been confirmed.
2. The effects of therapy in stone formers.
The mechanisms by which allopurinol may have 
reduced the formation of stones were obscure but may have 
been related to a reduction in the urinary urate excretion 
increasing the crystallisation inhibitory properties of
(127)
urine, or reducing the initiation of calcium oxalate 
crystal growth due to epitaxy. The novel observation of an 
increase in the urinary calcium excretion during 
allopurinol therapy may be considered to have been an 
adverse effect as far as stone disease was concerned, but 
the effect was only temporary.
Bendrofluazide therapy was shown to favourably 
alter the urinary excretion of both calcium and magnesium, 
with respect to the risk of forming renal stone, although, 
in the hypercalciuric group, the -urinary excretion of 
oxalate was increased.
The mode of action of bendrofluazide, particularly 
the hypocalciuric effect, is still obscure, and its 
influence on other factors related to the formation of 
stone was possible.
Although a reduction in the stone recurrence rate 
during therapy with allopurinol and bendrofluazide has 
been implied, the period of follow up has been too short 
to draw any definite conclusions as to the clinical 
effects of these therapies.
(128)
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